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Growth factor signaling promotes anabolic processes via activation of the
PI3K-Akt kinase cascade. Deregulation of the growth factor-dependent PI3K-Akt
pathway was implicated in tumorigenesis. Akt is an essential serine/threonine
protein kinase that controls multiple physiological functions such as cell growth,
proliferation, and survival to maintain cellular homeostasis. Recently, the
mammalian Target of Rapamycin Complex 2 (mTORC2) was identified as the
main Akt Ser-473 kinase, and Ser-473 phosphorylation is required for Akt
hyperactivation. However, the detailed mechanism of mTORC2 regulation in
response to growth factor stimulation or cellular stresses is not well understood.
In the first project, we studied the regulation of the mTORC2-Akt signaling
under ER stress. We identified the inactivation of mTORC2 by glycogen synthase
kinase-3β (GSK-3β). Under ER stress, the essential mTORC2 component, rictor,
is phosphorylated by GSK-3β at Ser-1235. This phosphorylation event results in
the inhibition of mTORC2 kinase activity by interrupting Akt binding to mTORC2.
Blocking rictor Ser-1235 phosphorylation can attenuate the negative impacts of
GSK-3β on mTORC2/Akt signaling and tumor growth. Thus, our work
demonstrated that GSK-3β-mediated rictor Ser-1235 phosphorylation in response
to ER stress interferes with Akt signaling by inhibiting mTORC2 kinase activity.
v

In the second project, I investigated the regulation of the mTORC2 integrity.
We found that basal mTOR kinase activity depends on ATP level, which is tightly
regulated by cell metabolism. The ATP-sensitive mTOR kinase is required for
SIN1 protein phosphorylation and stabilization. SIN1 is an indispensable subunit of
mTORC2 and is required for the complex assembly and mTORC2 kinase activity.
Our findings reveal that mTOR-mediated phosphorylation of SIN1 is critical for
maintaining complex integrity by preventing SIN1 from lysosomal degradation.
In sum, our findings verify two distinct mTORC2 regulatory mechanisms via
its components rictor and SIN1. First, GSK-3β-mediated rictor Ser-1235
phosphorylation results in mTORC2 inactivation by interfering its substrate binding
ability. Second, mTOR-mediated Ser-260 phosphorylation of SIN1 preserves its
complex integrity. Thus, these two projects provide novel insights into the
regulation of mTORC2.
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Chapter 1
Introduction





1.1 Growth factor-dependent PI3K-Akt signaling pathway
Growth factors have been identified as the autocrine peptide ligands
secreted by cells to regulate cell survival, proliferation, and differentiation
(Cantley, 2002; Engelman et al., 2006; Fruman et al., 1998).

When growth

factors bind to their specific receptors, it results in activation of the receptor
tyrosine kinase that further initiates phosphorylation of the regulatory docking
proteins on tyrosine residues. These tyrosine-phosphorylated sites play an
important role to recruit regulatory proteins through Src Homology 2 (SH2)
domains and proline-rich binding SH3 domains (Schlessinger and Lemmon,
2003). These growth factor signaling-mediated protein-protein interactions
promote phosphatidylinositol-3 kinase (PI3K) activity (Cantley, 2002; Shaw and
Cantley, 2006). The well-defined downstream effector of the PI3K pathway is the
Akt, also known as protein kinase B (PKB) (Cantley, 2002; Testa and Bellacosa,
2001). Akt is a highly conserved serine/threonine protein kinase, and controls
various biological functions such as cell proliferation, growth, survival, and
metabolism. Perturbations of the PI3K-Akt signaling are associated with human
diseases, such as cancers and metabolic syndromes.

1.2 Downstream effectors and cellular functions of Akt
Akt kinase is a member of the AGC (protein kinase A, G, and C) kinase
family that act on a wide spectrum of substrates (Bellacosa et al., 2005). For
example, Akt regulates cell cycle through phosphorylation of the cell cycle
inhibitors p27 and p21 by causing their cytoplasmic retention (Viglietto et al.,





2002; Zhou et al., 2001a), and also through phosphorylation of the human
oncogene product MDM2, which degrades p53 tumor suppressor gene (Zhou et
al., 2001b). Akt regulates cell survival through inactivation of the pro-apoptotic
protein BAD (Datta et al., 1997; del Peso et al., 1997) and inhibition of the highly
conserved substrates identified as the FOXO transcription factors that drive the
expression of pro-apoptotic genes (Brunet et al., 1999). Akt controls metabolism
by suppressing glycogen synthase kinase-3 (GSK-3) and by stimulating glucose
transport and glycolysis (Cross et al., 1995; Kohn et al., 1996). The role of Akt
signaling in regulation of cell growth and cell size is linked to its up-regulation of
the mTOR pathway by the phosphorylation of tuberous sclerosis complex 2
(TSC2) (Inoki et al., 2002; Manning et al., 2002) and the proline-rich Akt
substrate of 40 kDa (PRAS40) (Sancak et al., 2007; Vander Haar et al., 2007).

1.3 Activation of Akt
In the process of the growth factor signaling, binding of the growth factors
to the receptors leads to activation and translocation of PI3K to the plasma
membrane.

Following

activation

of

phosphatidylinositols-3,4,5-triphosphates

PI3K
(PIP3),

and
Akt

accumulation

switches

its

of

cellular

localization to the plasma membrane by binding to PIP3 via its pleckstrin
homology (PH) domain at the N-terminal region (Figure 1-1). In addition to PH
domain, it has been recently reported that





Figure 1-1.

Growth factor signaling pathway

Receptors regulated by growth factors activate PI3 Kinase, which recruits
inactive Akt to the plasma membrane. Recent report demonstrates that
ubiquitination of Akt by TRAF6 is required for its membrane translocation.
Moreover, both phosphorylation events by PDK1 and mTORC2 are required for
full activation of Akt.





TRAF6 ubiquitinates Akt and assists its membrane translocation (Yang et al.,
2009). In the meantime, two residues of Akt are phosphorylated for its full
activation. The Thr-308 residue of Akt that locates on its activation loop is
phosphorylated by the phosphoinositide-dependent kinase (PDK1), and this
phosphorylation is required for kinase activity of Akt (Alessi et al., 1997;
Stephens et al., 1998). The second Ser-473 residue resides at the C-terminal
region of Akt, and has been defined as the hydrophobic regulatory site. Lately,
mTORC2 has been identified as the major Akt Ser-473 kinase (Sarbassov et al.,
2005).
Whether Thr-308 phosphorylation of Akt is dependent on Ser-473
phosphorylation is still controversial. In human cancer cells (HT-29 colon, A549
lung, HEK-293T kidney, HeLa cervical, and PC3 prostate), knockdown of mTOR
or rictor expression decreases Akt phosphorylation on both Ser-473 and Thr-308
sites (Sarbassov et al., 2005). In this setting, inhibition of mTORC2-mediated
Ser-473 phosphorylation results in the decreased Thr-308 phosphorylation of Akt,
indicating the importance of Ser-473 phosphorylation for Thr-308 phosphorylation.
Moreover, prior Ser-473 phosphorylation is required for PDK1 to phosphorylate
Thr-308 in the immortalized cells (Scheid et al., 2002). However, phosphorylation
of Akt Thr-308 is not affected by loss of Ser-473 phosphorylation in mTORC2deficient embryos and MEFs (Guertin et al., 2006). This difference reflects the
highly active state of the Akt signaling in cancer cells because Thr-308
phosphorylation of Akt can be boosted by its Ser-473 phosphorylation. In this
regard, mTORC2 signaling might be amplified to hyper-activate Akt signaling that





is engaged in tumor growth and progression. Thus, inhibition of mTORC2 in
cancer cells should give stronger effects on Akt signaling pathway than in normal
tissues.

1.4 Mammalian target of rapamycin (mTOR)
mTOR was initially identified as the target of rapamycin, which is applied
as a potential anti-cancer drug and a potent immunosuppressant. The effects of
rapamycin on inhibiting proliferation stem from the inactivation of mTOR, an
essential regulator of the highly-conserved growth pathway (Harris and Lawrence,
2003). mTOR contains 2,549 amino acids with the predicted molecular weight of
290 kDa. Structurally, mTOR possesses N-terminal tandem HEAT repeats,
followed by a FRB domain and a C-terminal kinase domain (Figure 1-2). HEAT
repeat is derived from four proteins Huntington, Elongation factor 3, PR65/A,
TOR, and is composed of repeated protein motifs (about 47 amino acid residues
that form two anti-parallel -helices and two turns). HEAT repeats compose a
rod-like helical structure for regulation of the protein-protein interaction. The FRB
domain is the C-terminal stretch of 100 amino acids, and is the docking site for
FKBP12/rapamycin complex. Recent reports indicated that the lipid second
messenger phosphatidic acid (PA) binds FRB domain and enhances mTOR
activity. However, the molecular mechanism of mTOR activation by PA remains
unclear. The mTOR kinase domain structurally resembles the kinase domain of
PI3K (a lipid kinase), but functions as a serine/threonine protein kinase.





Figure 1-2.

The domain structures of the TOR protein

In 1990s, yeast genetic screens first identified two rapamycin target genes, called
TOR 1 and 2. The high degree of conservation among species, from mammals to
yeast, strongly suggests that TOR is an essential cell growth regulator. mTOR is
a Serine/Threonine protein kinase with a predicted molecular weight of 290 kDa.
Structurally, mTOR contains multiple tandem HEAT repeats in the N-terminal
region followed by a FRB domain and a C-terminal kinase domain.





1.5 mTOR complexes
mTOR and its binding partner, mammalian lethal with SEC13 protein 8
(mLST8), exist at least in two distinct complexes (Figure 1-3). mLST8 is a small
subunit that contains seven WD40 repeats and physically associates with the
mTOR kinase domain (Jacinto et al., 2004; Sarbassov et al., 2004). Interaction
between mTOR and mLST8 is required for the kinase activity of mTOR (Kim et
al., 2003). The interaction between raptor and mTOR/mLST8 defines the mTOR
Complex 1 that regulates protein translation by phosphorylation of its substrates
4EBP1 (eIF4E binding protein 1) and S6K1 (p70 ribosomal protein S6 kinase 1)
(Fingar and Blenis, 2004). 4EBP1 binds translational initiator eIF4E and inhibits
cap-dependent mRNA translation under basal condition (Gingras et al., 2001).
Upon growth factor stimulation, mTORC1 phosphorylates 4EBP1 and relieves its
suppressive impact on eIF4E to initiate protein translation. S6K1 binds to eIF3
(eukaryotic initiation factor 3) and remains inactive (Holz et al., 2005). The
activated mTORC1 upon growth factor induction results in S6K1 phosphorylation
and activation. The active S6K1 phosphorylates ribosomal protein S6 to stimulate
protein translation and cell growth (Jeno et al., 1988; Thomas, 2002).
The second mTOR complex (mTORC2) is assembled by binding of
mTOR/mLST8 to rapamycin-insensitive companion of mTOR (rictor) and
mammalian SAPK interacting protein 1 (SIN1) (Jacinto et al., 2006; Jacinto et al.,
2004; Sarbassov et al., 2004). These two unique components SIN1 and rictor
most likely carry the regulatory functions of this kinase complex. Sin1 contains a





Figure 1-3.

Current models of the mTOR complexes

mTOR forms two structurally and functionally distinct molecular complexes:
mTORC1 and mTORC2. mTORC1 is composed of mTOR, raptor and mLST8
(also called GL), which is highly sensitive to rapamycin inhibition. The
rapamycin insensitive complex mTORC2 is composed of mTOR, mLST8, rictor
and SIN1. Both complexes were shown to regulate downstream targets through
phosphorylation on the hydrophobic motif.





N-terminal Conserved Region In the Middle (CRIM) domain, the Raf-like Ras
binding domain (RBD) and a C-terminal PH domain (Schroder et al., 2007).
CRIM domain is a highly conserved region in the SIN1 family. SIN1 RBD domain
suggests that Ras is a potential regulator of mTORC2. SIN1 PH domain implies
the mTORC2 localization at the plasma membrane. However, the functional roles
of these domains are yet to be characterized.
Rictor is a more conserved and larger protein than SIN1. The human rictor
protein contains 1,708 amino acids and its sequence analysis did not reveal any
homology to known functional domains or proteins (Sarbassov et al., 2004). In
spite of this, rictor is a phospho-protein and the functional characterization of this
post-translational modification might provide insights in regulation of mTORC2. In
recent reports, some phosphorylation sites of rictor were identified, and the Thr1135

phosphorylation

is

the

growth

factor

dependent.

The

functional

characterization determined that S6K1 is the kinase of rictor Thr-1135, and this
site has been shown to carry the negative impact on mTORC2 by providing the
binding site for the 14-3-3 adaptor proteins (Dibble et al., 2009; Julien et al., 2010;
Treins et al., 2010). However, our functional studies indicated that this
phosphorylation occur independent of mTORC2. Importantly, rictor Thr-1135 site
was not essential for regulating mTORC2 kinase activity (Boulbes et al., 2010).

1.6 The mechanism of mTOR inhibition by rapamycin
Rapamycin binds proline isomerase FKBP12 to form a complex, which
specifically interacts with the FRB domain of mTOR and inhibits its function





(Figure 1-4) (Kim et al., 2002). In contrast, the FRB domain of mTOR within
mTORC2 is not accessible so that mTORC2 cannot be inhibited by rapamycin
binding. However, prolonged rapamycin treatment interferes with the assembly of
mTORC2. For examples, the prolonged rapamycin treatment results in less
abundance of mTORC2 and inhibition of Akt in several cell types, mostly
lymphoma cells (Sarbassov et al., 2006).

1.7 Downstream effectors of mTORC2
mTORC2 has been proposed to control phosphorylation of the AGC
kinases members including SGK1 (serum and glucocorticoid induced protein
kinase 1) (Garcia-Martinez and Alessi, 2008) and PKC (protein kinase C)
(Facchinetti et al., 2008; Ikenoue et al., 2008). mTORC2 has been identified as
the Ser-422 kinase of SGK1, which functions to stabilize the expression of the
ENaC (epithelial sodium channel) to induce sodium transport into epithelial cells
and maintain the sodium homeostasis (Loffing et al., 2006). Besides, mTORC2
controls the actin-cytoskeleton probably through phosphorylation of PKC on
Ser-657, but the detailed mechanism remains to be addressed.
The most critical finding about mTORC2 function is the confirmation of this
kinase complex as the major Akt kinase at the hydrophobic motif (HM) site Ser473 (Sarbassov et al., 2005). The functional role of mTORC2





Figure 1-4.

Rapamycin/FKBP12 binds and inhibits mTOR

Upon entering the cells, rapamycin binds a small protein receptor called FKBP12
(FK506-binding protein 12 kDa) to form a complex. This complex specifically
binds mTOR and inhibits its function.





as the regulatory kinase of Akt has been supported by the mouse genetic studies
(Guertin et al., 2006; Jacinto et al., 2006; Shiota et al., 2006; Yang et al., 2006).
In addition to Ser-473, mTORC2 has been shown to phosphorylate Akt on Thr450 turn motif (TM) site (Facchinetti et al., 2008; Ikenoue et al., 2008). Although
both sites are regulated by mTORC2, but their roles are different. Regulation of
the Akt HM site Ser-473 site is linked to the growth factor-mediated mTORC2
activation.

The

neighboring

TM

site

Thr-450

of

Akt

is

constitutively

phosphorylated by mTORC2 and is required to control Akt protein stability (Oh et
al., 2010). During Akt protein translation, mTORC2 can associate with the
actively translating ribosome and mediate the Thr-450 phosphorylation. This
phosphorylation event facilitates the proper folding of the Akt nascent polypeptide,
which prevents misfolded Akt from targeting for K48-linked ubiquitination and
proteasomal degradation.

1.8 Glycogen synthase kinase-3 (GSK-3)
Glycogen

Synthase

Kinase-3

(GSK-3)

is

a

multifunctional

and

evolutionally conserved serine/threonine protein kinase (Cohen and Frame,
2001). GSK-3 was discovered as the kinase of glycogen synthase that controls
glycogen metabolism (Cross et al., 1995). Two human genes encode GSK-3
isoforms, GSK-3 (51 kDa) and GSK-3 (46 kDa), which exhibit 84 % overall
identity and 98 % identity of their kinase domains. The major dissimilarity
between two isoforms is that GSK-3 contains an extra N terminal glycine-rich
stretch. Besides, these GSK-3 isoforms are functionally distinct because GSK-3





cannot rescue the embryonically lethal phenotype of GSK-3 deficient mice
(Hoeflich et al., 2000). Several recent reports suggest the potential differences
between these two isoforms (Kerkela et al., 2008; MacAulay et al., 2007). For
examples, GSK-3 inhibition is more effective in causing NF-B- and cAMPresponsive element-dependent transactivation (Liang and Chuang, 2006). By
contrast, GSK-3 depletion has more robust effects in suppressing neuronal
death and improving glucose tolerance in skeletal muscle (Liang and Chuang,
2007; Patel et al., 2008).
GSK-3 function is regulated by its phosphorylation. The phosphorylation of
the N-terminal serine residue (GSK-3 on Ser-9; GSK-3 on Ser-21) decreased
their kinase activity. Certain kinases such as Akt, p90RSK, protein kinase A, and
protein kinase C could phosphorylate these serine residues. The phosphorylated
serine residue serves as a pseudo substrate that hinders the access of
substrates to the active site of GSK-3. By contrast, GSK-3 activity is enhanced by
phosphorylation of the tyrosine residue (GSK-3 on Tyr-216 and GSK-3 on Tyr279), which might take place by autophosphorylation or by additional tyrosine
kinases. The regulatory mechanism of the GSK-3 tyrosine phosphorylation
remains ill-defined (Frame and Cohen, 2001; Grimes and Jope, 2001).
Moreover, the priming phosphorylation of the substrate by another kinase
is required for GSK-3 function. The priming phosphorylation takes place on a
serine residue resided four amino acids C-terminal to the GSK-3 phosphorylation
site. For instance, casein kinase II performs the priming phosphorylation of





glycogen synthase, and the priming phosphorylation of -catenin by casein
kinase I are required for GSK-3 action (Fiol et al., 1987; Liu et al., 2002).

1.9 Biological functions of GSK-3
GSK-3 regulates various biological pathways such as Wnt/-catenin
(Seidensticker and Behrens, 2000) and Hedgehog pathways, apoptotic process,
and cell cycle. GSK-3 dysfunction results in multiple human diseases including
bipolar disorder, Alzheimer’s disease, cancer and diabetes. In the development
of type II diabetes, GSK-3 activation associates with insulin resistance. The
impaired response of peripheral tissues (muscle, fat and liver) to insulin signals
causes deficient glucose uptake (Tanabe et al., 2008). GSK-3 has been
reported to be activated under ER stress (Huang et al., 2009), and ER stress is
the potential cause of insulin resistance and type II diabetes (Ozcan et al., 2004).
Specific GSK-3 inhibitors stimulate insulin-dependent glucose uptake (Ring et
al., 2003). However, the mechanisms of the GSK-3-dependent insulin
resistance remain to be determined.





Chapter 2
Materials and Methods





2.1 Cell lines and culture
MEFs, HeLa, MDA-MB-435, HEK-293T and COS-7 cells were obtained
from the American Type Culture Collection and cultured in DMEM/F12 with 10%
FBS and penicillin/streptomycin in 5% CO2 at 37°C. Cell lines were cultured at a
density that allows cell division throughout the course of the experiment. MEFs
were transfected by Dreamfect reagent following the manufacturer's protocol.

2.2 Antibodies and reagents
Antibodies to Xpress, myc and V5 tag from Invitrogen; antibodies to
phospho-Ser2481 mTOR, phospho-Thr1135 and phospho-Ser1235 rictor, mTOR,
rictor, raptor, phospho-Ser260 SIN1, phospho-Ser473, phospho-Thr450 and
phospho-Thr308 Akt, Akt, phospho-Ser641 GS, GS, phospho-Ser9 and phosphoTyr216 GSK-3, GSK-3, GSK-3, phospho-Thr980 PERK, PERK, p27, S6K1,
phospho-Thr389 S6K1 from Cell Signaling Technologies; antibodies to rictor and
tubulin and horseradish peroxidase (HRP)-labeled anti-rabbit, anti-mouse, and
anti-goat secondary antibodies from Santa Cruz Biotechnology.
Reagents were obtained from the following sources: Dulbecco's modified
Eagle's medium (DMEM)/F12 from Life Technologies; fetal bovine serum (FBS)
from HyClone. FuGENE 6 transfection reagent and Complete protease inhibitor
cocktail from Roche Applied Science; protein G-Sepharose from Pierce; insulinlike growth factor I (IGF-1) from Peprotech; thapsigargin, tunicamycin, BIO and
SB-216763 from Sigma; Dreamfect transfection reagent from OZ Biosciences.





2.3 Letiviral shRNAs and plasmid DNAs
Lentiviral shRNAs targeting humanGSK-3 and GSK-3 were obtained
from Sigma (MISSION shRNA). The targeting sequences of the oligo-nucleotides
are as follows:
GSK-3 sense strand, GCTGAGCTGTTACTAGGACAA (NM_002093.2-974s1c1);
GSK-3 sense strand, CCCAAACTACACAGAATTTAA (NM_002093.2-1087s1c1);
GSK-3 sense strand, CGGACATCAAAGTGATTGGCA (NM_019884.1-473s1c1);
GSK-3 sense strand, CCTCTCTTCAACTTCAGTGCT (NM_019884.1-1375s1c1).

Lentiviral shRNAs targeting human mTOR were generated and applied as
described previously (Sarbassov et al., 2005).
The pcDNA3-hemagglutinin (HA)-GSK-3-wild type and pBabe-puro-GSK3 (S9A) were obtained from Addgene. Plasmids pRK5-myc-GCP2, -myc-rictor,
myc-raptor, myc-mTOR-WT, myc-mTOR-KD, HA-mLST8, and HA-tubulin were
kindly provided by David M. Sabatini (Whitehead Institute for Biomedical
Research, Cambridge, MA). The pcDNA3.1-Sin1.1-V5 and pcDNA4-Xp-rictor
were generated by the TOPO cloning system (Invitrogen).

2.4 Mutagenesis of rictor
The rictor complementary DNA (cDNA) from the pRK5 plasmid was resub-cloned to pcDNA4 by means of the Xpress tag with the pcDNA4/HisMax
TOPO TA Expression Kit from Invitrogen. The large size of the plasmid (11 kb) is
incompatible with the polymerase chain reaction (PCR)-based mutagenesis. To
decrease the size of the plasmid to 6 kb, we sub-cloned the fragment of rictor
containing the sequences of the phospho-mutants into pBluescript by Bgl II and





Not I digestion. The primers for mutagenesis were designed based on the
QuikChange

Primer

Design

Program

(http://www.stratagene.com).

The

pBluescript plasmid containing the rictor fragment was mutagenized with the
QuikChange II XL Mutagenesis Kit (Stratagene). After validation of mutations by
sequencing, the mutated rictor fragments were reinserted into the Xp-rictor
pcDNA4 plasmid by Bgl II and Not I digestion.

2.5 Retroviral production and infection
Retroviral vectors were propagated in and purified from XL-10 Gold
bacterial cells and co-transfected together with the VPR and VSVG plasmids
into actively growing cells. One day before transfection, HEK 293T cells (1.2 
106) were placed on 6-cm dishes in 3 ml of DMEM supplemented with 10% FBS.
For production of retroviruses, HEK 293T cells were transfected by the calcium
phosphate method with 3 mg of transfer vector pMSCV, 0.6 mg of envelope
coding plasmid VSVG, and 2.4 mg of Gag-pol-expressing plasmid.
Retroviruses were harvested 48 hours after transfection and centrifuged at
3,000g at 4°C for 15 min to eliminate any remaining HEK 293T cells. One day
before infection, cells to be infected were seeded in six-well plates. Viral
supernatant was added at a ratio of 1:1 to the culture medium in the presence of
polybrene (8 mg/ml), and the cells were centrifuged at 1,800 rpm for 45 min to
increase the infection rate. Cells were incubated with retroviruses for 24 hours. A
second infection was performed the next day following the same protocol. After





an additional 24 hours of recovery in regular medium, infected cells were
passaged and selected with puromycin (2 mg/ml for 2 days).

2.6 Immunoprecipitations and kinase assays
For immunoprecipitation experiments, the lysis buffer contained 0.3%
CHAPS instead of 1% Triton to preserve the integrity of the mTOR complexes.
Two micrograms of rictor antibody was added to the cleared cellular lysates (1
mg of protein content in 700 ml) and incubated with rotation at 4°C for 90 min.
After 1 hour of incubation with 40 ml of 50% slurry of protein G-agarose,
immunoprecipitates captured by protein G-agarose were washed four times with
CHAPS-containing lysis buffer and once with rictor-mTOR kinase buffer [25 mM
Hepes (pH 7.5), 100 mM potassium acetate, and 2 mM MgCl2].
For in vitro mTORC2 kinase reactions, immunoprecipitates were
incubated in a final volume of 15 ml at 37°C for 20 min in rictor-mTOR kinase
buffer containing 500 ng of inactive Akt1-GST and 1 mM ATP. The reaction was
stopped by the addition of 235 μl of ice-cold enzyme dilution buffer [20 mM Mops
(pH 7.0), 1 mM EDTA, 0.3% CHAPS, 5% glycerol, 0.1% 2-mercaptoethanol, and
bovine serum albumin (BSA; 1 mg/ml)]. After a quick spin, the supernatant was
removed from the protein G-agarose, and the 15-μl portion was analyzed by
immunoblotting for phospho-Ser473 Akt and total Akt. The pelleted protein Gagarose beads were also analyzed by immunoblotting to determine the
abundance of rictor, Sin1, and mTOR in the immunoprecipitates.





For in vitro GSK-3 kinase reaction, immunoprecipitates were prepared
from

MDA-MB-435

cell

lysates

with

rictor

antibody.

GSK-3

was

immunoprecipitated from lysates of human embryonic kidney (HEK) 293T cells
expressing GSK-3 that were treated with tunicamycin (2 μg/ml) for 3 hours
before cell harvest. In vitro GSK-3 kinase assays were performed at 37°C for 30
min in the final volume of 25 ml of GSK-3 kinase buffer containing 4 mM Mops
(pH 7.2), 2.5 mM -glycerophosphate, 1 mM EGTA, 0.4 mM EDTA, 4 mM MgCl2,
0.05 mM dithiothreitol (DTT), 40 μM BSA, and 1 mM ATP. Immunoprecipitates
captured by protein G-agarose were washed with rictor-mTOR kinase buffer for
subsequent in vitro mTORC2 kinase reactions as indicated above.

2.7 Cell lysis and immunoblotting
Cells were rinsed with ice-cold phosphate-buffered saline (PBS) before
lysis in buffer containing 40 mM Hepes (pH 7.5), 120 mM NaCl, 1 mM EDTA, 10
mM sodium pyrophosphate, 10 mM sodium glycerophosphate, 50 mM NaF, 1%
Triton X-100, and protease inhibitor cocktail (Roche Applied Science). The
scraped lysates were incubated for 20 min at 4°C to complete lysis. The soluble
fractions of cell lysates were isolated by centrifugation at 13,000 rpm at 4°C for
12 min. Samples of the cellular lysates containing an equal amount of proteins
were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to polyvinylidene difluoride (PVDF) membrane. Proteins were then
visualized by immunoblotting and detected with enhanced chemiluminescence
(ECL) with the Immobilon Western kit (Millipore).





2.8 Preparation of liver tissue extracts for immunoblotting
Powdered livers were homogenized on ice with a Teflon glass
homogenizer in 1 ml of ice-cold buffer [20 mM tris-HCl (pH 7.4), 20 mM NaCl, 1
mM EDTA, 20 mM -glycerophosphate, 5 mM EGTA, 1 mM DTT, and 1 mM
phenylmethylsulfonyl fluoride (PMSF)] containing 0.1% Tween 20 and were
centrifuged at 1,000g for 20 min at 4°C to pellet insoluble material. The protein
concentration of the supernatant was determined. Liver extract samples
(containing 50 to 100 mg of total protein) were subjected to SDS-PAGE in 7.5%
polyacrylamide gels followed by Western blot analysis with indicated antibodies.

2.9 Tumor xenografts
MEFs constitutively expressing wild-type, S1235A, or S1235D-rictor were
transformed by H-Ras overexpression. Protein extracts from wild-type-, S1235A-,
or S1235D-rictor-expressing MEFs indicated equal protein amounts of rictor and
H-Ras by Western blotting analysis. The MEFs (5  106 cells per mouse) were
injected

subcutaneously

into

the

upper

flank

region

of

6-week-old

immunodeficient nude mice (n = 5 for each group).
Tumor size was measured after 15 days and the tumor volume was
determined with the standard formula L  W2  0.5, where L is the longest length
and W is the shortest length in millimeters. The differences in the tumor volume
from mice injected by wild-type-, S1235A-, or S1235Drictor-expressing MEFs





were compared by one-way analysis of variance (ANOVA). Nude mice were
killed and the tumors were excised.

2.10 In vitro substrate binding assay
For the in vitro substrate binding assay, rictor immunoprecipitates were
incubated in a final volume of 15 ml at 37°C for 20 min in rictor-mTOR kinase
buffer

containing

100

ng

of

Akt1-GST

with

or

without

ATP.

The

immunoprecipitates were then washed four times with CHAPS-containing lysis
buffer. The pelleted protein G-agarose beads were analyzed by immunoblotting
to determine the protein abundance of Akt1-GST, rictor, Sin1, and mTOR in the
immunoprecipitates.

2.11 Drosophila RNAi and analysis
RNAi against Drosophila GSK-3 was performed as previously described
(Sarbassov et al., 2005). dsRNA targeting Drosophila GSK-3 was synthesized by
in vitro transcription (IVT) in 20-ml reactions with a MEGAscript T7 kit (Ambion).
DNA templates for IVT were generated by PCR from total Drosophila S2 cellular
genomic DNA. The primers (which incorporated a 5' and 3' T7 promoter) for
dGSK-3 dsRNA synthesis were as follows:
The dGSK-3 forward primer:
5'-TAATACGACTCACTATAGGCCGTTGACGAGTTTGTGTGT
The dGSK-3 reverse primer:
5'-TAATACGACTCACTATAGGAAACTCGGCGACTGTTTGTT





The underlined region indicates the T7 promoter sequence. The dsRNA products
were purified with an Invitrogen PureLink PCR Purification Kit. Final dsRNA
concentrations were measured on a Nano-Drop spectrophotometer.
Drosophila S2 cells were prepared for dsRNA addition by seeding 1  106
cells in 2 ml of Drosophila Schneider's medium to each well in six-well culture
plates. dsRNAs were transfected with FuGENE 6 (Roche). Briefly, 6 μl of
FuGENE was added to 94 μl of Drosophila SFM (Invitrogen) followed by the
addition of 4 mg of dGSK-3 dsRNA. Four micrograms of green fluorescent
protein (GFP) dsRNA was used as control. Tubes were gently mixed and
incubated for 20 min at room temperature. FuGENE-dsRNA complexes were
then administered to cells by adding the entire mixture drop-wise around wells
and then swirling to ensure even dispersal. After 6 hours of dsRNA addition, the
medium was changed to avoid potential negative effects of FuGENE on cell
viability. Additional FuGENE-dsRNA complexes were added to wells on each of
the following 3 days. After 4 days of incubation to allow turnover of the target
mRNAs, cell lysates were subjected to immunoblotting for the amounts of
phospho- and total dAkt, GSK-3, and tubulin.

2.12 Purification of the soluble FLAG-mLST8/myc-mTOR heterodimer
FLAG-mLST8 was co-transfected with myc-mTOR cDNA in HEK-293T
cells. After a 48 h transfection, cells were washed with cold PBS, lysed with 0.3%
CHAPS buffer, and incubated with mild agitation for 20 min at 4 °C. The lysate
was transferred to the spinning columns for centrifugation for 15 min at 10,000





rpm. After centrifugation, the supernatant was used for the FLAG affinity
purification as described previously (Yip et al., 2010). FLAG M2 affinity resins
were washed three times in 0.3% CHAPS lysis buffer and packed into a 10 ml
Bio-Rad column. The cellular lysates were applied through the column seven
times. After running the lysates, the column was washed with 20 ml of lysis buffer
and 10 ml of elution buffer (40 mM HEPES, pH 7.4, 500 mM NaCl, 0.1% CHAPS).
The FLAG-mLST8/myc-mTOR heterodimer was eluted by the elution buffer with
0.5 mg/ml of the FLAG peptide. The eluted fractions from number 2 to 6 were
combined, dialyzed with mTORC2 kinase buffer, and concentrated with Millipore
Amicon Ultra-15 centrifugal filter units. The purified FLAG-mLST8/myc-mTOR
heterodimer was analyzed by immunoblotting and applied for the in vitro
mTORC2 assembly.

2.13 The in vitro mTORC2 assembly and kinase reaction
Myc-rictor and SIN1-V5 cDNAs were co-transfected in HEK-293T cells.
After 48-h transfection, cells were washed with cold PBS, lysed with 0.3%
CHAPS buffer, and subjected for centrifugation for 15 min at 10,000 rpm. The
supernatant was applied for immunoprecipitation with anti-V5 antibody. The mycrictor/SIN1-V5 immunoprecipitates were incubated with or without the purified
soluble FLAG-mLST/myc-mTOR heterodimer at room temperature for 2 h in
mTORC2 kinase buffer with 1 mM ATP. After washing three times with 0.3%
CHAPS lysis buffer, the immunoprecipitates were used for the in vitro mTORC2
kinase reaction with wild-type Akt as the substrate.





Chapter 3
ER stress inhibits mTORC2-Akt signaling
through GSK-3-mediated phosphorylation of rictor
Most of this work has been published in:
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S.-W. Lee, J. Wu, H.-K. Lin, D. D. Sarbassov, ER stress inhibits mTORC2
and Akt signaling through GSK-3–mediated phosphorylation of rictor. Sci.
Signal. 4, ra10 (2011).





Rationale
Although the functional role of mTORC2 as the major regulatory Ser-473
kinase of Akt is well established, the regulatory mechanisms of mTORC2
remains poorly characterized. Within mTORC2, the essential components rictor
and SIN1 most likely carries the regulatory functions of this kinase complex.
Particularly, rictor is a phospho-protein and the functional characterization of this
post-translational modification might provide insights in regulation of mTORC2. In
this study, I aimed to identify rictor phosphorylation site(s) that is essential for
mTORC2 regulation.
Growth factor signaling is sensitive to certain stress conditions, such as
endoplasmic reticulum (ER) stress. ER stress is a common pathophysiological
state associated with metabolic and neuronal disorders as well as human
cancers. Here, we found that inhibition of the mTORC2 and Akt signaling by ER
stress is associated with the increased rictor phosphorylation on Ser-1235. This
phosphorylation event occurs in mouse tissues under ER stress condition,
suggesting that rictor Ser-1235 has a biological function and could potentially
affect the mTORC2 kinase activity. Therefore, I initiated this research project to
further investigate whether mTORC2 kinase activity is suppressed under ER
stress. I also aimed to identify the kinase for rictor Ser-1235 phosphorylation, and
to determine the biological functions of rictor Ser-1235 phosphorylation.

Results





3.1. ER stress-mediated inhibition of Akt signaling associates with rictor
phosphorylation at Ser-1235
To address if the mTORC2 activity is sensitive to stress condition, we
analyzed its activity and rictor phosphorylation in response to osmotic stress.
Acute osmotic stress induced by treatment of cells with 0.5 M sorbitol caused
inhibition of the mTORC2-Akt signaling, which was shown by the substantial
decrease of the mTORC2 kinase activity and Akt Ser-473 phosphorylation
(Figure 3-1A). Notably, the osmotic stress induced by sorbitol led to increased
rictor phosphorylation at Ser-1235 as shown in cell lysate and rictor
immunoprecipitate (Figure 3-1A). Osmosis of water from cells is linked to ER
stress induction (Lee and Linstedt, 1999). Our initial experiment in tissue culture
of cancer cells indicates a stress-inducible phosphorylation of rictor on Ser-1235.
We hypothesized that if this site has a biological function, this phosphorylation
event would also occur in mouse tissues under ER stress.
Thapsigargin and tunicamycin are two well-characterized compounds
known to induce ER stress. Thapsigargin is an inhibitor of SERCA
(sarco/endoplasmic reticulum calcium ATPase). Thapsigargin inhibits the cell to
transport calcium to the endoplasmic and sarcoplasmic reticula and results in the
elevated cytosolic calcium concentration. The disruption of homeostatic balance
of the Ca2+ concentration in the ER leads to ER stress induction.





Figure 3-1.

Inhibition of mTORC2 signaling by ER stress is linked to rictor

phosphorylation.
(A) Inhibition of mTORC2 activity by osmotic stress correlates with rictor Ser1235 phosphorylation. HEK 293T cells were incubated with 0.5 M sorbitol for 30
min to induce osmotic stress. Rictor immunoprecipitates (IP) were used for in
vitro kinase assays with full-length wild-type Akt1 as the substrate. (This figure
was adopted from our previously published work in Sci. Signal. 4, ra10, 2011; the
permission was received from the journal.)





Tunicamycin blocks the N-linked protein glycosylation and causes incorrect
protein folding and membrane targeting. The accumulation of the misfolded
proteins triggers ER stress. To extend our cellular data to the in vivo study, we
injected mice with both compounds to induce ER stress and analyzed the mouse
liver extracts. The induction of ER stress was indicated by phosphorylation of the
ER stress marker PERK (protein kinase RNA-like endoplasmic reticulum kinase)
at Thr-980 (Figure 3-1B). Similarly, ER stress resulted in decreased Akt Ser-473
phosphorylation and augmented rictor Ser-1235 phosphorylation. The data
implied that Ser-1235 is a novel ER-stress-inducible rictor phosphorylation site.

3.2.

Inhibition

of

GSK-3

prohibits

ER

stress-mediated

Ser-1235

phosphorylation of rictor and up-regulates mTORC2 kinase activity
Based on the sequence alignment result, the surrounding sequence of
rictor Ser-1235 (SS-S1235-PS) resembles the BCL-3 (B cell lymphoma 3-encoded
protein) Ser-394 (SS-S394-PS) site known to be phosphorylated by GSK-3.
Importantly, the GSK-3 kinase activity is inducible by ER stress (Song et al.,
2002). Thus, it is possible that stress-induced rictor phosphorylation at Ser-1235
is regulated by GSK-3. Indeed, treatment of cells with tunicamycin and
thapsigargin led to GSK-3 activation, as shown by the increased tyrosine
phosphorylation of GSK-3 at Tyr-216 (Hughes et al., 1993; Wang et al., 1994)
and the elevated phosphorylation of the GSK-3 substrate, glycogen synthase
(GS) at Ser-641 (Figure 3-2A). Moreover, inhibition of GSK-3 in stressed cells by





Figure 3-1.

Inhibition of mTORC2 signaling by ER stress is linked to rictor

phosphorylation.
(B) Regulation of rictor Ser-1235 phosphorylation by ER stress in mice.
Thapsigargin (1 μg/g in PBS) or tunicamycin (2 μg/g in 150 mM glucose) was
injected intraperitoneally into 4-month-old mice for 24 hours to induce ER stress.
(This figure was adopted from our previously published work in Sci. Signal. 4, ra10, 2011;
the permission was received from the journal.)





Figure 3-2.

ER stress–dependent phosphorylation of rictor at Ser-1235

and mTORC2 signaling requires GSK-3 activity.
(A) GSK-3 mediates ER stress-induced phosphorylation of rictor at Ser-1235.
MDA-MB-435 cells were treated with 2 μM thapsigargin (TG) or tunicamycin (TM)
(2 μg/ml) for 6 hours, and then with 5 mM of the GSK-3 kinase inhibitor BIO for 3
hours before cell harvest. (This figure was adopted from our previously published work
in Sci. Signal. 4, ra10, 2011; the permission was received from the journal.)





6-bromoindirubin-3-oxime
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rictor
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rictor

phosphorylation. The ER stress-mediated dephosphorylation of Akt was also
dependent on GSK-3 function, demonstrating that Akt Ser-473 phosphorylation is
inversely correlated with rictor Ser-1235 phosphorylation.
We further studied if GSK-3 regulates Akt signaling in cell culture
mediums containing high (10 %) or low (1 %) serum. Inhibition of GSK-3 by two
distinct inhibitors, BIO and SB-216763, promoted Akt Ser-473 and Thr-308
phosphorylation in both high- and low-serum conditions (Figure 3-2B). So,
inhibition of GSK-3 suffices to activate Akt signaling in different conditions, which
is coherent to recent reports that GSK-3 inhibitors cause Akt-dependent
phenotypes including glucose uptake and cell proliferation (Mussmann et al.,
2007; Ring et al., 2003).
Because inhibition of GSK-3 also reduced rictor phosphorylation at Ser1235, we reasoned that GSK-3 inhibition-dependent Akt activation may associate
with the changes of mTORC2 activity. To examine this idea, we immunopurified
mTORC2 from cells treated with or without GSK-3 inhibitors and conducted the in
vitro mTORC2 kinase assay using full length GST-Akt as the substrate. We
detected a higher kinase activity of mTORC2 with GSK-3 inhibition (Figure 3-2C).
These results indicated that inhibition of GSK-3 augments mTORC2 kinase
activity; moreover, this impact was coherently accompanied with the declined
rictor phosphorylation at Ser-1235.





Figure 3-2.

ER stress–dependent phosphorylation of rictor at Ser-1235

and mTORC2 signaling requires GSK-3 activity.
(B) GSK-3 inhibitors induce Akt activation. MDA-MB-435 cells were incubated
with 5 μM BIO or 10 μM SB-216763 for 5 hours under low- or high-serum (1 or
10% FBS, respectively) conditions. (This figure was adopted from our previously
published work in Sci. Signal. 4, ra10, 2011; the permission was received from the
journal.)





Figure 3-2.

(C) Inhibition of GSK-3 induces mTORC2 kinase activity. MDA-

MB-435 cells were incubated with BIO or SB-216763 as in Figure 3-2B under
low-serum conditions. Rictor immunoprecipitates were used for in vitro kinase
assays with full-length WT Akt1 as the substrate. (This figure was adopted from our
previously published work in Sci. Signal. 4, ra10, 2011; the permission was received
from the journal.)





3.3. The inhibitory regulation of mTORC2 and Akt by GSK-3 are conserved
in Drosophila
Alignment of rictor orthologs indicates that the first 1,000 amino acids of
human rictor protein (total 1,708 amino acids) are highly conserved among
eukaryotes (Sarbassov et al., 2004), and Ser-1235 residue is conserved in
vertebrates (Figure 3-3A). Although the first 1,000 amino acids conserved region
of human rictor sequence poorly aligns with the invertebrate Drosophila
melanogaster rictor sequence, a small region within the adjacent sequence of
human rictor Ser-1235 (from amino acids 1209 to 1238) does align with its
Drosophila ortholog (from amino acids 1209 to 1237) with a potential
phosphorylation site at Ser-1233 (Figure 3-3B). Thus, we reasoned that TORC2
and Akt regulation by GSK-3 is possibly conserved in the Drosophila. To address
this possibility, we performed GSK-3 inhibition in Drosophila S2 cells. Under lowserum (1% FBS) condition, Drosophila Akt (dAkt) phosphorylation at the TORC2dependent Ser-505 residue (Sarbassov et al., 2005) increased after BIO
treatment (Figure 3-3C). There is solely single gene in Drosophila encoding
GSK-3. We knocked down this gene with double-stranded RNA (dsRNA)mediated RNA interference (RNAi) (Sarbassov et al., 2005). Knockdown of GSK3 promoted dAkt phosphorylation at Ser-505 (Figure 3-3D), implying that Akt
activity was inhibited by GSK-3 in Drosophila cells. In addition, GSK-3 was
required for declined dAkt Ser-505 phosphorylation under ER stress (Figure 33E).





Figure 3-3.

The conservation of the rictor S-1235 site

(A) The Ser-1235 site in rictor is conserved in vertebrates. Rictor vertebrate
ortholog

protein

sequences

were

aligned

with

HomoloGene

website

(http://www.ncbi.nlm.nih.gov/homologene).
(B) The alignment of human and Drosophila sequences within the area of the
Ser-1235 site in human rictor.
(These figures were adopted from our previously published work in Sci. Signal. 4, ra10,
2011; the permission was received from the journal.)





Figure 3-3.

GSK-3-dependent regulation of Akt is conserved in the

invertebrate fly Drosophila melanogaster
(C) Similar to mammalian cells, Akt phosphorylation is increased by inhibition of
GSK3 in Drosophila S2 cells. Drosophila S2 cells were incubated in 1% FBS
containing Drosophila Schneider’s medium for 16 hours and then treated with 20
μM BIO for 3 hours.
(D) Knockdown of GSK3 in Drosophila S2 cells induces phosphorylation of Akt.
GSK3 and GFP dsRNAs were transfected with Fugene 6 into S2 cells. After four
days, S2 cells were collected and analyzed by Immunoblotting.
(E) Phosphorylation of Akt in Drosophila S2 cells is regulated by ER stress.
Drosophila S2 cells with or without GSK-3 knockdown were treated with
thapsigargin (10 μM) for 24 hours.
(These figures were adopted from our previously published work in Sci. Signal. 4, ra10,
2011; the permission was received from the journal.)





3.4. GSK-3 is required for rictor phosphorylation at Ser-1235
Our data demonstrated that ER stress-dependent rictor phosphorylation
and mTORC2 inactivation is dependent on GSK-3 activity. In human, there are
two structurally similar but functionally distinct GSK-3 isoforms: GSK-3 and
GSK-3. The selective GSK-3 inhibitors SB-216763 and BIO recognize the ATPbinding pocket of GSK-3, which shares structural similarity in GSK-3 and GSK3. Therefore, it is unlikely that GSK-3 inhibitors could discriminate between the
two isoforms. To examine if both isoforms are required for rictor Ser-1235
phosphorylation, we knocked down each isoform employing two different
shRNAs specifically targeting GSK-3 or GSK-3. Depletion of GSK-3 rather
than GSK-3 prevented rictor Ser-1235 phosphorylation (Figure 3-4A).
We further determined the role of GSK-3 in regulation of rictor
phosphorylation and Akt signaling by using GSK-3-deficient MEFs. Switching
GSK-3 wild-type MEFs from high- to low-serum conditions caused raised rictor
Ser-1235 phosphorylation, and this elevated phosphorylation was linked to
reduced Akt Ser-473 phosphorylation (Figure 3-4B). By contrast, we did not
observe the same effects in GSK-3-null MEFs that were switched from high- to
low-serum conditions (Figure 3-4B). Moreover, we analyzed the impact of ER
stress to wild-type and GSK-3-deficient MEFs. Wild-type MEFs displayed
similar ER stress response as that of human cancer cells (Figure 3-2A); however,
ER stress induction did not promote rictor





Figure 3-4.

GSK-3 is required for ER stress-induced phosphorylation of

rictor at Ser-1235 and inhibition of Akt signaling.
(A) Phosphorylation of rictor at Ser-1235 in cells requires GSK-3. shRNAs
targeting luciferase, GSK-3, or GSK-3 were lentivirally transduced into MDAMB-435 cells.
(B) Phosphorylation of rictor at Ser-1235 was not detected and phosphorylation
of Akt at Ser-473 phosphorylation was increased in GSK-3-null MEFs. GSK3+/+ and GSK-3/ MEFs were incubated with 10 or 1% FBS-containing
medium for 16 hours.
(These figures were adopted from our previously published work in Sci. Signal. 4, ra10,
2011; the permission was received from the journal.)





phosphorylation at Ser-1235 or suppress Akt Ser-473 phosphorylation in GSK3-deficient MEFs (Figure 3-4C). Previous findings showed that these two GSK-3
isoforms have distinct functions (Hoeflich et al., 2000; Lee et al., 2007; Ruel et al.,
1993). Our results expanded the notion that GSK-3, instead of GSK-3, controls
rictor Ser-1235 phosphorylation and inhibits Akt signaling in response to ER
stress.

3.5. GSK-3 phosphorylates Ser-1235 of rictor and inhibits mTORC2 kinase
activity
Since GSK-3-mediated rictor phosphorylation caused declining of the
mTORC2 activity, we inferred that augment of GSK-3 protein level might also
affect mTORC2 function. Certainly, overexpression of GSK-3 is effective to
inhibit the kinase activity of mTORC2, which was linked to increased rictor
phosphorylation at Ser-1235 (Figure 3-5A). Although rictor phosphorylation at
Ser-1235 is dependent on the presence of GSK-3 and its activity, we could not
make a conclusion that GSK-3 is the direct kinase of rictor. Thus, we further
tested if GSK-3 could directly phosphorylate rictor by performing the in vitro
GSK-3 kinase assay. Incubation of the immunopurified mTORC2 with or without
active GSK-3 showed that GSK-3 directly phosphorylated Ser-1235 of rictor
(Figure 3-5B). Following the in vitro GSK-3 kinase reaction, we applied the
immunopurified mTORC2 for the kinase assay and found that its kinase activity
decreased when rictor was phosphorylated by GSK-3 at Ser-1235 (Figure 35B). Furthermore,





Figure 3-4.

GSK-3 is required for ER stress-induced phosphorylation of

rictor at Ser-1235 and inhibition of Akt signaling.
(C) GSK-3-null MEFs show resistance to ER stress–dependent Akt inactivation.
GSK-3+/+ and GSK-3/ MEFs were treated with tunicamycin (2 μg/ml) for 6
hours. (This figure was adopted from our previously published work in Sci. Signal. 4,
ra10, 2011; the permission was received from the journal.)





Figure 3-5.

GSK-3 phosphorylates rictor at Ser-1235 and inhibits

phosphorylation of Akt by mTORC2.
(A) GSK-3 overexpression enhances phosphorylation of rictor at Ser-1235 and
inhibits phosphorylation of Akt by mTORC2. Rictor immunoprecipitates were
prepared from lysates of COS-7 cells transfected with WT or mutant GSK-3 and
used for in vitro kinase assays with full-length WT Akt1 as the substrate. (This
figure was adopted from our previously published work in Sci. Signal. 4, ra10, 2011; the
permission was received from the journal.)





Figure 3-5.

GSK-3 phosphorylates rictor at Ser-1235 and inhibits

phosphorylation of Akt by mTORC2.
(B) GSK-3 phosphorylates rictor at Ser-1235 and inhibits phosphorylation of Akt
by mTORC2. GSK-3 was immunopurified from HEK 293T cells transfected with
GSK-3; cells were treated with tunicamycin (2 μg/ml) for 3 hours before harvest.
Rictor immunoprecipitates were prepared from MDA-MB-435 cell lysates. The in
vitro GSK-3 kinase assays were performed on rictor immunoprecipitates. As a
control, GSK-3 was preincubated with 10 μM BIO before the kinase reaction.
The in vitro mTORC2 kinase assays were subsequently performed on rictor
immunoprecipitates. (This figure was adopted from our previously published work in
Sci. Signal. 4, ra10, 2011; the permission was received from the journal.)





rictor phosphorylation was eliminated by inhibition of GSK-3, demonstrating that
GSK-3, but not a contaminating kinase, directly phosphorylated rictor at Ser1235. Therefore, GSK-3 inhibits mTORC2 kinase activity by directly
phosphorylating rictor on Ser-1235.

3.6. Blocking Ser-1235 phosphorylation of rictor prevents mTORC2
inactivation by GSK-3
We reasoned that if rictor Ser-1235 were the main regulatory site of GSK3, mutation on this site would alter GSK-3-dependent regulation of mTORC2
function. We over-expressed either wild-type rictor or its Ser-1235 to Ala
(S1235A) phospho-mutant that prevents phosphorylation in rictor-deficient MEFs.
We detected higher Akt Ser-473 phosphorylation in the rictor S1235A mutantexpressing MEFs in comparison with those expressing wild-type rictor (Figure 36A). In addition, overexpression of GSK-3 led to decreased Akt Ser-473
phosphorylation in the presence of wild-type rictor. On the contrary, mTORC2mediated Akt phosphorylation was not changed by overexpression of GSK-3 in
the context of rictor S1235A mutant (Figure 3-6A). Thus, mutation of the rictor
Ser-1235 is sufficient to prevent the mTORC2 inactivation by GSK-3.
Likewise, we observed more intense Akt Ser-473 phosphorylation in MEFs
stably expressing the rictor S1235A in comparison with those expressing wildtype rictor or the Ser-1235 to Aspartic acid (S1235D) mutant that mimics
phosphorylation (Figure 3-6B). We further investigated ER stress responses in





Figure 3-6.

Blocking

Ser-1235

phosphorylation

of

rictor

prevents

mTORC2 inactivation by GSK-3.
(A) GSK-3 inhibits Akt phosphorylation by phosphorylation of rictor at Ser-1235.
Rictor-null MEFs grown in 10% serum were transfected with cDNAs encoding
WT rictor or the S1235A mutant and with increasing amounts of GSK-3 cDNA.
(This figure was adopted from our previously published work in Sci. Signal. 4, ra10, 2011;
the permission was received from the journal.)





Figure 3-6.

Blocking Ser-1235 phosphorylation of rictor maintains higher

mTORC2 activity.
(B) Stable expression of the rictor S1235A phospho-mutant shows high basal
phosphorylation of Akt that is insensitive to ER stress. Rictor-null MEFs
constitutively expressing WT rictor or the phospho-mutants were treated with
tunicamycin (0.3 μg/ml) for 8 hours. (This figure was adopted from our previously
published work in Sci. Signal. 4, ra10, 2011; the permission was received from the
journal.)





the MEFs restored with wild-type rictor or its phospho-mutants. Treatment of
tunicamycin equally induced ER stress and GSK-3 activation in all cell lines
(Figure 3-6B). However, Akt phosphorylation at Ser-473 did not decline under ER
stress in the rictor S1235A-expressing MEFs (Figure 3-6B). This suggested that
Ser-1235 of rictor is important for the GSK-3 impacts on mTORC2 and Akt
signaling. Surprisingly, the S1235D mutant-expressing MEFs (which mimics
constitutive rictor Ser-1235 phosphorylation) remained sensitive to ER stress at
the level similar to that detected in the wild-type rictor-reconstituted MEFs. This
inferred that ER stress suppresses Akt signaling not only by interfering with
mTORC2 activity, but also by inhibiting upstream regulator of mTORC2 in the
growth factor/PI3K signaling.
It is interesting that single rictor phosphorylation event can alter the activity
of a huge protein complex (about 550 kD). Several possible mechanisms might
be accountable for the impact of rictor Ser-1235 phosphorylation on mTORC2
activity, such as destruction of complex integrity or interference of the substrate
binding. To test which notion is correct, we first analyzed the integrity and activity
of the mTORC2 reconstituting either wild-type rictor or its phospho-mutants. We
observed similar amount of intact mTORC2 from MEFs expressing rictor wild
type, S1235A, or S1235D-mutant (Figure 3-6C), suggesting that neither of the
phospho-mutants changes the complex integrity of mTORC2. Consistently,
kinase activity of the rictor S1235A-containing mTORC2 was higher than that of
mTORC2 complexes restoring either wild-type rictor or S1235D mutant (Figure 36C, upper panel). This scenario occurred in the complexes from the





Figure 3-6.

Blocking Ser-1235 phosphorylation of rictor maintains higher

mTORC2 kinase activity.
(C) Increased phosphorylation of Akt is observed with mTORC2 complexes
containing the rictor S1235A mutant. Rictor immunoprecipitates from rictor-null
MEFs stably expressing WT rictor or the phospho-mutants and grown in 10 or
1% serum for 16 hours were used for in vitro kinase assays. (This figure was
adopted from our previously published work in Sci. Signal. 4, ra10, 2011; the permission
was received from the journal.)





high- or low-serum cell culture conditions. The data demonstrated that rictor Ser1235 phosphorylation regulates mTORC2 kinase activity, but not complex
integrity.

3.7. GSK-3-mediated rictor phosphorylation at Ser-1235 hinders the
mTORC2 substrate binding
Since rictor in conjunction with SIN1 regulates substrate specificity of
mTORC2, the phosphorylation of rictor at Ser-1235 might affect the binding of
Akt to mTORC2. To test this hypothesis, we developed the mTORC2 substratebinding assay in which the immunopurified mTORC2 was incubated with full
length GST-Akt1 protein in the absence of ATP. Following incubation, the
unbound proteins were thoroughly washed, and the protein level of GST-Akt
bound to mTORC2 was analyzed by immunoblotting. First, we examined the
interaction between mTORC2 and Akt in cells treated with tunicamycin or sorbitol
(ER-stressed). We detected less GST-Akt protein bound to mTORC2 that was
purified from ER stressed cells in comparison with control cells (Figure 3-7A).
Therefore, ER stress causes deficient substrate binding ability of mTORC2,
leading to mTORC2 inactivation. Given that ER stress-dependent mTORC2
inactivation requires GSK-3, GSK-3-mediated rictor phosphorylation at Ser1235 may influence mTORC2 substrate binding. Accordingly, we further
analyzed the impacts of the rictor phospho-mutantion on the Akt binding ability of
mTORC2. The equal amount of mTORC2 purified from rictor wild





Figure 3-7.

Phosphorylation of rictor at Ser-1235 inhibits mTORC2 kinase

activity by interfering with mTORC2 binding to Akt.
(A) ER stress inhibits mTORC2 substrate binding. MDA-MB-435 cells were
treated

with

tunicamycin

or

sorbitol

(Sorb.)

to

induce

stress.

Rictor

immunoprecipitates were used for the in vitro substrate binding assays with
WTGST-Akt as the substrate and analyzed by immunoblotting. (This figure was
adopted from our previously published work in Sci. Signal. 4, ra10, 2011; the permission
was received from the journal.)





type, S1235A, or S1235D-mutant restored MEFs was employed for GST-Akt
binding assay. The mTORC2 complex carrying wild-type rictor interacted with
more GST-Akt compared to control (Figure 3-7B, left panel). In comparison with
mTORC2 carrying wild-type rictor, the rictor S1235A phospho-mutant containing
complex exhibited stronger GST-Akt binding ability; in contrast, the complex
containing rictor S1235D phospho-mutant bound less amount of the substrate.
The interaction of mTORC2 with its substrate was transient and dynamic since
the binding was undetectable if ATP exists in the reaction buffer (Figure 3-7B,
right panel). By contrast, when ATP is absent, the GST-Akt is inefficiently
released from mTORC2. Under this setting, the bound GST-Akt protein amount
represents the Akt-binding capacity of mTORC2. Therefore, these results
demonstrated that the molecular mechanism of the mTORC2 inactivation caused
by rictor Ser-1235 phosphorylation was due to interference of Akt binding to
mTORC2.

3.8. GSK-3-mediated rictor phosphorylation at Ser-1235 controls cell
proliferation and tumor growth
Our findings showed that GSK-3-dependent rictor phosphorylation at
Ser-1235 declines the mTORC2-Akt signaling. Since Akt controls cell
proliferation, we inferred that rictor S1235A mutation may more strongly induce
cell proliferation in comparison with wild-type rictor or the S1235D mutation. To
test this possibility, we assessed the proliferation rate of these stable MEFs
reconstituted with equal amount of the wild-type rictor and its phospho-mutants





Figure 3-7.

Phosphorylation of rictor at Ser-1235 inhibits mTORC2 kinase

activity by interfering with mTORC2 binding to Akt.
(B) Phosphorylation of rictor at Ser-1235 regulates mTORC2 substrate binding.
Rictor immunoprecipitates from rictor-null MEFs stably expressing WT rictor or
the phospho-mutants were used for the in vitro substrate binding assays with WT
GST-Akt as the substrate. (This figure was adopted from our previously published
work in Sci. Signal. 4, ra10, 2011; the permission was received from the journal.)





(Figure 3-8A, left panel). Restoration of the wild-type rictor into rictor-deficient
MEFs augmented cell proliferation rate by 2.27 times. Restoration of the rictor
S1235A mutant promoted cell proliferation more potently than the wild-type rictor
(2.67 times in comparison with non-restored rictor-deficient MEFs and 30 %
higher than rictor-WT restored MEFs). In contrast, MEFs restored with the rictor
S1235D mutant displayed lower cell proliferation capacity (1.83 times related to
non-restored rictor-deficient MEFs; 50 % less than rictor-WT restored MEFs)
(Figure 3-8A, right panel). Notably, the cell proliferation rate of the rictor S1235Arestored MEFs was twice higher than that of the rictor S1235D-restored MEFs.
This finding indicates that GSK-3-mediated rictor Ser-1235 phosphorylation is
critical for controlling cell proliferation.
To expand our findings to the in vivo tumor xenograft system, we analyzed
the impacts of rictor Ser-1235 phosphorylation on subcutaneous tumor growth.
First, MEFs restored with rictor-WT or its phospho-mutants were transformed by
overexpressing H-Ras (Figure 3-8B, left panel). Mice injected with the rictor
S1235A-restored MEFs developed larger tumors in comparison with those
injected with rictor-WT-restored MEFs (Figure 3-8B, right panel; Figure 3-8C). On
the contrary, mice injected with MEFs containing the rictor S1235D mutation
generated smaller tumors than those injected with either WT or S1235A rictorexpressing MEFs (Figure 3-8B, right panel; Figure 3-8C). The data demonstrated
that rictor Ser-1235 phosphorylation is significant for controlling cell proliferation
and tumor growth.





Figure 3-8. Phosphorylation of rictor at Ser-1235 inhibits cell proliferation.
(A) WT rictor or the phospho-mutants were reintroduced into rictor-null MEFs
with the lentiviral expression system. Cell proliferation measurements were
performed by counting cells after 48 hours. The ratio of proliferation rate was
graphed with GraphPad Prism 5 software. *P < 0.001 for all pair wise
comparisons; one-way ANOVA, post hoc intergroup comparisons with HolmSidat test. (This figure was adopted from our previously published work in Sci. Signal. 4,
ra10, 2011; the permission was received from the journal.)





Figure 3-8.

Phosphorylation of rictor at Ser-1235 inhibits tumor growth.

(B) MEFs described in Figure 3-7A were transformed by overexpression of the
oncogenic form of H-Ras and injected into 6-week-old immunodeficient nude
mice (n = 5 for each group; 5  106 cells per mouse). Tumor size was measured
after 15 days, the tumor sizes were calculated, and the volumes were presented
by histogram. *One-way ANOVA, post hoc intergroup comparisons with HolmSidat test; the P values are indicated. (C) Mice injected with MEFs expressing
each form of rictor were killed and representative images of the excised tumors
are shown. (These figures were adopted from our previously published work in Sci.
Signal. 4, ra10, 2011; the permission was received from the journal.)





3.9. Discussion
Although ER stress is linked to inhibition of the Akt signaling in the
pathogenesis of human diseases, the molecular mechanisms of how ER stress
inhibits Akt signaling remain to be defined. In our study, we observed that ER
stress induces GSK-3-mediated rictor phosphorylation at Ser-1235, which
suppresses mTORC2 kinase activity by impeding its substrate binding (Figure 39). Our study provides a novel insight to fill the gaps of knowledge and clarifies
the overlooked balance between two kinases, Akt and GSK-3. Initially, GSK-3
has been identified as the substrate of Akt. Now, our study outlines the
importance and mechanism that GSK-3, the highly conserved and essential
kinase in all eukaryotes, controls the anabolic growth factor signaling. This
finding transforms GSK-3 from Akt substrate to the dominant stress-dependent
regulator of Akt. It explains how ER stress inhibits growth factor signaling and
how GSK-3 carries the tumor suppressive effect.
In terms of GSK-3-mediated phosphorylation, most GSK-3 substrates
need priming phosphorylation at adjacent sites to promote the phosphorylation
by GSK-3. Nevertheless, several GSK-3 substrates do not require priming
step, such as cyclin D1 and BCL3 (Diehl et al., 1998; Viatour et al., 2004).
Besides, there is no serine residue at the adjacent priming site of rictor for prior
phosphorylation. The resemblance of phosphorylation sites between rictor and
BCL3 implies that priming phosphorylation is not required for GSK-3-mediated
rictor phosphorylation at Ser-1235. Our study also indicates that GSK-3-





Figure 3-9.

The proposed working model for the first project.

Initially, GSK-3 has been identified as the substrate of Akt. In my first project,
we showed that under ER stress rictor is phosphorylated by GSK-3 at Ser-1235.
This phosphorylation event causes inhibition of mTORC2 kinase activity by
interfering with substrate binding.





mediated mTORC2 regulation is evolutionally conserved in vertebrates and
invertebrate fly Drosophila melanogaster.
In

addition,

our

finding

indicates

that

one

specific

Ser-1235

phosphorylation on rictor inhibits Akt binding ability of the multi-protein complex
(approximately 550 kDa). Other phosphorylation sites of rictor in proximity to Ser1235 including the Thr-1135 and Ser-1177 sites do not affect mTORC2 activity
(Boulbes et al., 2010). Accordingly, we inferred that rictor Ser-1235 site locates in
proximity to the Akt-binding pocket of mTORC2 and this phosphorylation event
interrupts

with

Akt

binding

to

mTORC2.

In

addition,

rictor

Ser-1235

phosphorylation did not disrupt the complex integrity of mTORC2, indicating that
Ser-1235 residue does not locate near the binding site of rictor to its interacting
partners.
Furthermore, previous mouse genetic models are consistent with our
study in which GSK-3 obstructs the insulin-dependent Akt signaling, providing a
link between GSK-3 and insulin resistance (Srinivasan et al., 2005; Tanabe et
al., 2008). This explains why GSK-3 inhibitors act as the insulin-mimetic agents
by stimulating glucose uptake and cell proliferation. GSK-3 becomes a
promising target for treating multiple human diseases such as metabolic
disorders (Cohen and Goedert, 2004; Rayasam et al., 2009). Hence, our finding
connects clinical applications of GSK-3 inhibitors with activation of mTORC2/Akt
signaling, and is particularly significant in development of these inhibitors for
effective treatment of metabolic disorders. So far, most GSK-3 inhibitors could
not distinguish between GSK-3 and GSK-3 because they are ATP competitive





inhibitors and the ATP binding sites of these two isoforms are very similar. To
overcome the low specificity of this type of GSK-3 inhibitors, the development of
the non-ATP competitive inhibitors (e.g. substrate competitive inhibitors) is very
important. However, the substrate competitive inhibitors have a disadvantage
that they usually bind weakly to the kinase (just like the dynamic substrateenzyme interaction). So, chemical modifications are required to improve the
efficacy of the substrate competitive inhibitors by enhancing their binding affinity
to GSK-3.
In our study, GSK-3 is highly activated under ER stress due to the
observation that the phosphorylation of its substrate glycogen synthase (Ser-641)
and auto-phosphorylation site (Tyr-216) (Chen et al., 2011). However, how ER
stress controls GSK-3 activity remains scarcely characterized. It is important to
address this question in the future. Our preliminary study also indicates that
GSK3-dependent rictor Ser-1235 phosphorylation is linked to a biphasic effect
on mTORC2. As an immediate effect we observe inhibition of the mTORC2
kinase activity, and as a long-term effect we detect an accelerated degradation of
rictor. It is common that most of the known substrates of GSK3 are rapidly
degraded by proteosomal pathway where GSK3-mediated phosphorylation
serves as a recognition motif for the -Trcp E3 ubiquitin ligase (Xu et al., 2009). It
will be interesting to identify the mechanism for the Ser-1235 phosphorylationdependent rictor degradation.





Chapter 4
The homeostatic ATP sensor mTOR maintains
the mTORC2 complex integrity
The first part of this work has been published in:
C.-H. Chen, D. D. Sarbassov, The mTOR (Mammalian Target of
Rapamycin) Kinase Maintains Integrity of mTOR Complex 2. The
Journal of Biological Chemistry Vol. 286, No. 46, 40386-40394 (2011)
The second part of this work has been submitted to Molecular Cell Journal





Rationale
The central component of the growth signaling mTOR assembles into two
structurally and functionally different complexes (mTORC1 and mTORC2). The
second complex, mTORC2, is a multi-protein kinase composed of mTOR,
mLST8, SIN1 and rictor. In my last project (Chapter 3), we demonstrated that
one specific rictor phosphorylation at Ser-1235 inhibits Akt binding of mTORC2.
However, the regulatory mechanism of the mTORC2 complex integrity is not well
characterized.
In this study, I developed a reconstitution system of mTORC2 by coexpression of its essential components (mTOR, mLST8, rictor, and SIN1), and
observed that the mTOR-dependent SIN1 phosphorylation is critical for
maintaining complex integrity by preventing SIN1 degradation. SIN1 is a critical
component for mTORC2 complex formation and its kinase activity. Thus, I aimed
to investigate the mechanism how mTOR kinase regulates integrity of mTORC2.

Results
4.1. The mTORC2 reconstitution by co-expression of its four components
According to previous studies, mTORC2 components display distinct
binding affinity (Frias et al., 2006; Sarbassov et al., 2004). A mild cell lysis buffer
containing the CHAPS detergent could maintain the assembly of this kinase
complex, whereas mTORC2 dissociates to two heterodimers (rictor/SIN1 and
mTOR/mLST8) under stringent lysis condition with the Triton X-100 detergent.
The biochemical studies suggest that the initial stage of the mTORC2 formation





is the dimerization of the mTOR/mLST8 and rictor/SIN1, respectively. Then,
these two heterodimers assemble a relatively low affinity hetero-tetramer that is
sensitive to the stringent lysis buffer containing Triton X-100.
First, we tested the formation of the rictor/SIN1 heterodimer by coexpressing rictor and SIN1. The V5-tagged SIN1 was co-transfected with the
myc-tagged rictor, GCP2, or raptor cDNAs (Figure 4-1A, lower panel).
Immunopurification via the myc antibody showed that SIN1 only bound to rictor
rather than the control proteins GCP2 and raptor (Figure 4-1A, upper panel).
Moreover, the interaction between rictor and SIN1 is required to stabilize mutual
expression since SIN1 is highly unstable without its binding partner rictor (Frias
et al., 2006). In order to reach the equivalent SIN1 expression, the five-fold
amount of SIN1 cDNA was co-transfected with the control proteins GCP2 or
raptor. Similarly, the co-expression of mTOR and mLST8 showed the formation
of the mTOR/mLST8 heterodimer (Figure 4-1B). We observed that mTOR
specifically interacted with mLST8 but not tubulin by pulling down myc-mTOR.
Thus, the initial step of our reconstitution studies indicated the specific assembly
of the rictor/SIN1 and mTOR/mLST8 heterodimers.
Subsequently, we generated the reconstituted mTORC2 by co-expression
of its four recombinant components (Figure 4-1C). After immunopurification of
myc-mTOR, we analyzed its binding proteins and observed that SIN1 or rictor
itself does not interact with mTOR/mLST8 heterodimer. We also detected low





Figure 4-1.

Reconstitution

of

the

functional

mTORC2

complex

by

expressing its recombinant components.
(A) Rictor interacts with SIN1. SIN1-V5 plasmid DNA was co-transfected with
myc-rictor into HEK-293T cells by Lipofectamine 2000, and cells were analyzed
48 h following transfection. Cell lysates were applied for immunoprecipitation (IP)
with anti-myc antibody. The immunoprecipitates and cell lysates were analyzed
by immunoblotting with anti-myc and anti-V5 antibodies.
(B) mTOR interacts with mLST8. Myc-mTOR construct was co-transfected with
HA-mLST8 in HEK-293T cells. The negative control is presented by expressing
HA--tubulin with myc-mTOR. (These figures were adopted from our previously
published work in Journal of Biological Chemistry Vol. 286, No. 46, 40386-40394, 2011;
the permission was received from the journal.)





Figure 4-1.

Reconstitution

of

the

functional

mTORC2

complex

by

expressing its recombinant components.
(C) Interaction of mTOR with other mTORC2 components. The differently tagged
recombinant components of mTORC2 were transiently expressed in HEK-293T
cells, and the assembled complexes were purified by the immunoprecipitation of
myc-mTOR. (This figure was adopted from our previously published work in Journal of
Biological Chemistry Vol. 286, No. 46, 40386-40394, 2011; the permission was received
from the journal.)





protein abundance of SIN1 and rictor alone because rictor/SIN1 heterodimer
formation is required to stabilize their expression. Similarly, mTOR itself did not
bind to rictor/SIN1 heterodimer, suggesting that the heterotrimer does not form
during the mTORC2 assembly. When all four components of mTORC2 were cotransfected, we observed the functional mTORC2 formation as shown by the in
vitro mTORC2 kinase assay (Figure 4-1C). Our study of the mTORC2
reconstitution system is consistent to the previous findings that SIN1, rictor and
mLST8 are indispensable components for the assembly and function of
mTORC2 (Frias et al., 2006; Guertin et al., 2006; Jacinto et al., 2006).
Importantly, the endogenous mTORC2 components do not interfere with the
recombinant mTORC2 reconstituted by transiently expressed mTOR, mLST8,
rictor, and SIN1.
We further examined if the reconstituted mTORC2 is regulated by growth
factor signaling as the endogenous complex by analysis of its activity in growth
factor responsive COS-7 cells (Roudabush et al., 2000). After co-transfection of
the mTORC2 components, we stimulated the serum-starved COS-7 cells by IGF1 and immunopurified the reconstituted mTORC2 followed by the in vitro kinase
reaction (Figure 4-1D). The mTORC2 purified from cells grown in 10% serum
showed the low basal kinase activity and the complex from serum-starved cells
did not exhibit kinase activity. In contrast, we observed the robust kinase activity
of mTORC2 in IGF-stimulated cells. Thus, the reconstituted mTORC2 resembles
its native form that is also controlled by growth factor signaling.





Figure 4-1.

Reconstituted mTORC2 kinase activity was stimulated by IGF-

1. (D) The differently tagged recombinant components of mTORC2 were
transiently expressed in COS-7 cells, and the assembled complexes were
purified by the immunoprecipitation of myc-mTOR. Lane 1, COS-7 cells
expressing recombinant mTORC2 was cultured in growth medium containing
10% serum. Lanes 2 and 3, COS-7 cells expressing recombinant mTORC2 were
cultured in serum-free medium for 16 h and then treated without or with IGF-I
(100 ng/ml) for 30 min, respectively. (This figure was adopted from our previously
published work in Journal of Biological Chemistry Vol. 286, No. 46, 40386-40394, 2011;
the permission was received from the journal.)





4.2. Reconstitution of mTORC2: The kinase activity of mTOR is required for
Akt Ser-473 phosphorylation
In the process of the growth factor-dependent Akt activation, the Ser-473
phosphorylation is required to stabilize the active conformation of Akt (Pearce et
al., 2010). Characterization of the Ser-473 kinase (PDK2) will provide a novel
insight for the Akt regulation. Recent biochemical and mouse genetic studies
clarified mTORC2 as the major Ser-473 kinase of Akt (Guertin et al., 2006;
Jacinto et al., 2006; Sarbassov et al., 2005; Shiota et al., 2006; Yang et al., 2006).
Although mTOR serves as the kinase within mTORC2, there was no direct
evidence indicating mTOR as the Ser-473 kinase of Akt. In order to characterize
the role of the mTOR kinase within mTORC2, we employed the reconstitution of
mTORC2 carrying the kinase-dead form of mTOR. We co-transfected the cDNAs
of the wild-type or kinase-dead mTOR with other essential mTORC2 components
and analyzed the mTORC2 activity in the duplicate experiments. The mTORC2
reconstituted with the kinase-dead mTOR did not exhibit kinase activity (Figure 42A), indicating the essential role of the mTOR kinase domain for the kinase
activity of mTORC2. Previous reports suggested that Akt auto-phosphorylation at
Ser-473 occurs in regulation of Akt (Toker and Newton, 2000). To characterize
the potential impact of Akt auto-phosphorylation, we performed the kinase
reaction by using the kinase-inactive form of GST-Akt. The reconstituted wildtype mTORC2 exhibited the robust kinase activity toward the kinase-inactive
form of GST-Akt, demonstrating that Akt auto-phosphorylation does not take
place during the mTORC2-mediated Akt phosphorylation (Figure 4-2A).





Figure 4-2.

Critical role of mTOR kinase activity in mTORC2 function.

(A) The kinase-dead mTOR forms inactive mTORC2 and causes deficiency in
assembly of the complex. The study has been performed in duplicate: Xpressrictor, SIN1-V5, and HA-mLST8 constructs were co-transfected with myc-mTOR
wild type (WT) (lanes 1 and 2) or myc-mTOR kinase-dead (KD) (lanes 3 and 4) in
HEK-293T cells. Immunoprecipitates (IP) prepared with anti-myc antibody were
used for the in vitro kinase assay with wild-type or kinase-dead Akt as the
substrate. (This figure was adopted from our previously published work in Journal of
Biological Chemistry Vol. 286, No. 46, 40386-40394, 2011; the permission was received
from the journal.)





In the subsequent analysis, we found that the kinase-dead mTOR did not
interrupt expression and interaction with its binding partner mLST8; however, it
resulted in the declined expression of rictor and SIN1, which led to ineffective
formation of the mTORC2 (Figure 4-2A). In addition, SIN1 protein displayed the
slower migratory form in the complex with wild-type mTOR rather than kinasedead mTOR (Figure 4-2A). This indicated that mTOR kinase activity might be
required for SIN1 protein modification, which is linked to regulation of SIN1
protein stability. The experiment in Figure 4-2A showed that the kinase-dead
mTOR caused a profound impact on the rictor and SIN1 expression that resulted
in low abundance of mTORC2. To overcome the uneven mTORC2 assembly, we
optimized the formation of the complex with wild-type mTOR by co-expressing
only 30 % of the SIN1 cDNA (Figure 4-2B). The comparable amounts of the
immunopurified mTORC2 complexes assembled with mTOR-WT or mTOR-KD
were applied for in vitro kinase assay. Contrary to mTOR-WT, the mTORC2
reconstituted with kinase-dead mTOR again did not exhibit the kinase activity.
Similarly, the SIN1 co-expressed with mTOR-WT showed the slower mobility in
the gel, indicating that SIN1 protein modification is dependent on mTOR kinase
activity. Collectively, our analysis showed that mTOR kinase within mTORC2 is
required for mTORC2 function as the Akt Ser-473 kinase, and also contributes to
the regulation of SIN1 through protein modification.





Figure 4-2.

Critical role of mTOR kinase activity in mTORC2 function.

(B) The study similar to that in Figure 4-2A was performed by optimizing
expression and assembly of the mTORC2 assembled with the wild-type or the
kinase-dead mutant of mTOR. To optimize expression, the myc-mTOR-WT was
co-transfected with Xpress-rictor, 30% of SIN1-V5, and HA-mLST8 constructs in
HEK-293T cells (lanes 1 and 2). (This figure was adopted from our previously
published work in Journal of Biological Chemistry Vol. 286, No. 46, 40386-40394, 2011;
the permission was received from the journal.)





4.3. Phosphorylation of SIN1 occurs upon assembling into mTORC2
complex in vitro
Our data shown in Figure 4-2 indicate that SIN1 protein abundance and its
modification depend on the mTOR kinase activity. Most likely, the observed SIN1
protein modification is caused by phosphorylation. To test this possibility, we
reconstituted and purified mTORC2 followed by phosphatase treatment (Figure
4-3A). Only the active form of phosphatase changed the SIN1 mobility from the
slower to faster migratory form, suggesting that SIN1 is phosphorylated within
mTORC2 assembled with wild-type mTOR.
To further investigate if SIN1 is the mTOR substrate, we examined the
mTOR-mediated SIN1 phosphorylation by the in vitro mTORC2 assembly. First,
we purified the co-expressed FLAG-mLST8/myc-mTOR heterodimer by FLAG
peptide elution. Then, the immunopurified myc-rictor/V5-SIN1 heterodimer bound
to protein G-agarose beads was incubated with soluble FLAG-mLST8/mycmTOR heterodimer. After co-incubation, the protein G-agarose beads were
thoroughly washed and analyzed for the complex formation and kinase activity of
mTORC2. Indeed, these two heterodimers have integrated to mTORC2 as
shown by its four components (Figure 4-3B). The in vitro assembled mTORC2
exhibited kinase activity toward Akt Ser-473. In addition, SIN1 protein changed
mobility to the slower migratory form following in vitro mTORC2 reconstitution
(Figure 4-3B), resembling its phosphorylated form before phosphatase treatment
(Figure 4-3A). These results indicated that SIN1 is the mTOR substrate.





Figure 4-3.

SIN1 is a substrate of mTOR.

(A) SIN1 as a component of mTORC2 is a phospho-protein. Myc-mTOR-WT
cDNA was co-transfected with Xpress-rictor, Sin1-V5, and HA-mLST8 cDNAs in
HEK-293T cells. Cell lysates were applied for immunoprecipitation with anti-V5
antibody. The immunoprecipitates were incubated with or without calf intestinal
phosphatase (CIP) or inactive CIP (pretreated with 50 mM EDTA). CIP treatment
resulted in a faster migratory form of SIN1, suggesting that the mobility shift of
SIN1 band is indeed due to phosphorylation/dephosphorylation. (This figure was
adopted from our previously published work in Journal of Biological Chemistry Vol. 286,
No. 46, 40386-40394, 2011; the permission was received from the journal.)





Figure 4-3.

SIN1 is a substrate of mTOR.

(B) SIN1 as a component of mTORC2 is a substrate of mTOR. In vitro mTORC2
kinase assay was performed by incubation of two heterodimers, rictor/SIN1 and
mTOR/mLST8. First, FLAG purification was conducted from HEK-293T cells with
FLAG-mLST/myc-mTOR co-transfection. Then, the purified soluble FLAGmLST/myc-mTOR

heterodimer

was

incubated

with

immunopurified

myc

rictor/SIN1-V5 by the V5 antibody at room temperature for 2 h in mTORC2
kinase buffer with 1 mM ATP. After washing three times with 0.3% CHAPS lysis
buffer, the immunoprecipitates were used for the in vitro mTORC2 kinase
reaction by using wild-type Akt as the substrate. (This figure was adopted from our
previously published work in Journal of Biological Chemistry Vol. 286, No. 46, 4038640394, 2011; the permission was received from the journal.)





4.4. The lysosomal degradation of SIN1 protein is caused by the inactive
mTOR kinase
Our data suggested that SIN1 protein expression is dependent on the
mTOR-mediated SIN1 phosphorylation. To further inspect the regulation of SIN1
by mTOR kinase, we studied SIN1 protein half-life by the inhibition of protein
synthesis. As described in Figure 4-2B, we normalized the reconstituted
mTORC2 by reducing SIN1 expression with wild-type mTOR. Following
cycloheximide treatment, we detected the shorter SIN1 protein half-life in the
mTOR-KD co-expression (Figure 4-4A), suggesting that declined SIN1 protein
level results from accelerated protein degradation. The quantification of the
immunoblotting image of SIN1 displayed the greater effect of mTOR-KD on
diminishing the SIN1 half-life approximately eight times in comparison with
mTOR-WT (Figure 4-4B).
The ubiquitin-proteasomal and lysosomal degradation are two major
representatives of protein degradation pathways. To verify which pathway
regulates SIN1 protein degradation, we reconstituted mTORC2 with the mTORKD form in cells and studied effects of MG132 (proteasome inhibitor) or
chloroquine (lysosome inhibitor). The Skp2-mediated proteasomal pathway is
required for the degradation of the cell cycle regulator p27 protein (Carrano et al.,
1999). We observed the considerable increase of the p27 protein after MG132
treatment (Figure 4-4C) revealing that the drug was effective in inhibition of the
proteosomal pathway. However, the suppression of the proteosomal pathway did
not block SIN1 degradation as shown by the low SIN1 protein amount in the





Figure 4-4.

mTOR kinase activity stabilizes SIN1 by preventing its

lysosomal degradation.
(A) Optimized reconstitution of mTORC2 by co-expression of its components was
performed as in Figure 4-2B. 48 h following transfection, cells were treated with
20 μg/ml cycloheximide and lysed at the indicated time points. (This figure was
adopted from our previously published work in Journal of Biological Chemistry Vol. 286,
No. 46, 40386-40394, 2011; the permission was received from the journal.)





Figure 4-4.

mTOR kinase activity stabilizes SIN1 by preventing its

lysosomal degradation.
(B) Graphic represents mTOR kinase-dependent SIN1 half-life shown in (A).
SIN1-V5 signals were quantified by GelPro 4.5 software. The half-life of SIN1 coexpressed with mTOR-WT is shown as filled circles, and its half-life when coexpressed with mTOR-KD is shown as open circles. (This figure was adopted from
our previously published work in Journal of Biological Chemistry Vol. 286, No. 46,
40386-40394, 2011; the permission was received from the journal.)





Figure 4-4.

mTOR kinase activity stabilizes SIN1 by preventing its

lysosomal degradation.
(C) myc-mTOR-KD or its wild-type construct was co-transfected with Xpressrictor, SIN1-V5, and HA-mLST8 constructs into HEK-293T cells. After 48-h
transfection, cells were treated with 30 μM MG132 or 100 μM chloroquine and
collected at the indicated time points. (This figure was adopted from our previously
published work in Journal of Biological Chemistry Vol. 286, No. 46, 40386-40394, 2011;
the permission was received from the journal.)





presence or absence of MG132. Only the lysosomal inhibitor chloroquine led to
elevated SIN1 protein level comparable to that in the co-expression of the wildtype mTOR (Figure 4-4C). Thus, these results demonstrated that SIN1
degradation caused by deficient mTOR kinase is dependent on lysosomal
degradation pathway.

4.5. Endogenous SIN1 protein level depends on mTOR expression and its
kinase activity
Our findings based on the recombinant mTORC2 reconstitution system
indicated that protein stability of SIN1 depends on mTOR kinase activity. To
confirm our results, we validated if mTOR regulates the endogenous SIN1
protein. Indeed, the knockdown of mTOR by expressing specific shRNAs led to
the declined protein amount of the endogenous SIN1 (Figure 4-5A). This
negative impact correlates well with the mTOR knockdown efficiency since the
smaller SIN1 protein amount is observed in cells containing the shRNA#2, which
causes the stronger suppressive effect on the mTOR protein level.
Next, we addressed if mTOR inhibition is able to mimic the impact on
SIN1 protein stability by mTOR-KD. We applied the highly specific mTOR
inhibitor TORIN in MDA-MB-435 cells (Liu et al., 2010; Thoreen et al., 2009),
which resulted in a potent mTOR inactivation as shown by the dephosphorylation of the mTORC2 substrate Akt (Ser-473 and Thr-450) and the
mTORC1 substrate S6K1 (Thr-389) (Figure 4-5B). TORIN also inhibited the
mTOR auto-phosphorylation at Ser-2481 (Peterson et al., 2000). By contrast, the





Figure 4-5.

Endogenous SIN1 expression is dependent on mTOR kinase

activity.
(A) SIN1 protein abundance decreased with a loss of mTOR. The mTOR
knockdown has been performed by the lentiviral expression of two shRNAs in
HeLa cells. A nonspecific luciferase shRNA was used as a control. (This figure
was adopted from our previously published work in Journal of Biological Chemistry Vol.
286, No. 46, 40386-40394, 2011; the permission was received from the journal.)





Figure 4-5.

Endogenous SIN1 expression is dependent on mTOR kinase

activity.
(B) mTOR kinase activity controls abundance of SIN1. MDA-MB-435 cells were
incubated with specific mTOR inhibitor (0.5 μM TORIN) for 24 or 48 h. (This figure
was adopted from our previously published work in Journal of Biological Chemistry Vol.
286, No. 46, 40386-40394, 2011; the permission was received from the journal.)





PDK1-dependent Akt phosphorylation at Thr-308 has been stimulated by the
mTOR kinase inactivation, which is consistent to the previous report (Peterson et
al., 2009). This outcome is likely due to the compensatory effect caused by the
mTORC2-dependent inhibition of Akt. Notably, the prolonged mTOR inhibition by
TORIN led to a considerable reduction of the endogenous SIN1 protein level
(Figure 4-5B). Therefore, our results demonstrate that mTOR and its kinase
activity is required for protein expression of SIN1 within either endogenous or
reconstituted mTORC2.

4.6. SIN1 protein abundance and mTORC2 integrity is regulated by the
amount of cellular glucose
Previous research suggested that nutrient signals positively regulate
mTOR activity. In the absence of the amino acids in cells, it showed strong
reduction of the mTORC1 activity. Moreover, AMPK negatively regulates
mTORC1/S6K activity under energy deprivation. However, how mTORC2
responds to the nutrient or energy depletion is still unclear. According to our
study of the mTORC2 reconstitution, the mTOR kinase activity is required for
maintaining SIN1 protein stability and integrity of mTORC2. To identify the
physiological conditions that cause mTOR dysfunction and SIN1 degradation, we
studied the metabolic stress conditions in cells. Glucose is the essential energy
source for cells to produce ATP; amino acids are the key elements for protein
synthesis. MDA-MB-435 and HeLa cells were incubated in mediums without
glucose or amino acids for 20 hours (Figure 4-6A).





Figure 4-6.

Glucose starvation, but not amino acid deprivation, causes

rictor and SIN1 protein degradation and mTORC2 dissociation.
(A) Decreased SIN1 and rictor protein abundance under glucose starvation is
associated with reduced basal mTORC2 activity toward Akt Thr-450. MDA-MB435 and HeLa cells were incubated with glucose-free or amino acid-free
mediums for 20 hours, respectively. Immunoblotting was used to detect
phosphorylation of Akt at Thr-450 and the amount of the indicated proteins in the
cell lysates.
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phosphorylation of Akt at Thr-450, which is a well-characterized constitutive
phosphorylation site of mTORC2 (Facchinetti et al., 2008; Ikenoue et al., 2008).
Because rictor stability requires its binding to SIN1, we detected rictor
degradation due to less SIN1 protein abundance after glucose depletion. In
contrast, we did not have the similar observation from cells cultured in amino
acid-free medium.
SIN1 is an essential component of mTORC2 and required for complex
formation. By pulling down mTOR from cells under glucose starvation at the
shorter time point (16 hours), we found that SIN1 and rictor did not bind mTOR
efficiently (Figure 4-6B). Under this setting, the dissociation of raptor from mTOR
was associated with the elevated AMPK-dependent raptor phosphorylation at
Ser-792. It suggests that AMPK might play a role in the regulation of mTORC1
assembly. The above results indicated that integrity of mTORC2 and mTORC1 is
sensitive to glucose depletion, but not amino acid starvation.

4.7. The mTOR Kinase functions as the ATP sensing component of
mTORC2
Why glucose deprivation causes mTORC2 inactivation, dissociation and
SIN1 degradation? Glucose is the essential source for generating ATP. We
measured ATP level from cells under glucose starvation and found that cellular
ATP ratio gradually decreased in the time-dependent manner (Figure 4-7A).
Previous study showed that mTOR has lower ATP binding ability and is a





Figure 4-6.

Glucose starvation, but not amino acid deprivation, causes

rictor and SIN1 protein degradation and mTORC2 dissociation.
(B) Deficient complex integrity of the mTORC1 and mTORC2 is caused by
glucose deprivation. MDA-MB-435 cells were incubated with glucose-free
medium for 10, 16 and 20 hours or amino acid-free medium for 20 hours,
respectively. The mTOR immunoprecipitates were prepared from cell lysates to
examine the complex formation of the mTORC1 and mTORC2.





Figure 4-7.

Cellular ATP ratio gradually decreases under glucose

starvation condition with the time-dependent manner.
(A) MDA-MB-435 cells were incubated with glucose-free medium for 0, 3, 6, 9, 12
and 15 hours, and collected for quantitative detection of ATP by luciferase driven
bioluminescence assay (Roche ATP Bioluminescence Assay Kit CLS II). Three
independent experiments were shown for each condition.





homeostatic ATP sensor (Dennis et al., 2001). Thus, a cellular ATP level may
directly affect mTOR kinase activity. To prove this, we immunopurified mTORC2
and analyzed the in vitro mTORC2 kinase activity toward Akt under different ATP
concentrations (Figure 4-7B). We detected the highest kinase activity of
mTORC2 at the concentration of ATP above the 1.2 mM range, whereas most
protein kinases require about 0.1 mM ATP for full activation (Dennis et al., 2001).
Using the same ATP titration conditions for mTORC1, we obtained similar results
for Thr-389 phosphorylation of S6K1 by mTORC1 purified by raptor
immunoprecipitation (Figure 4-7C). These findings support the role of mTOR
kinase as the ATP sensor. We also interpret that mTORC2 kinase activity
declined under glucose starvation is mediated by ATP depletion. Since SIN1
protein stability depends on its phosphorylation by mTOR, the mTORC2 kinase
activity highly sensitive to the ATP depletion under glucose starvation led to SIN1
degradation and complex dissociation.

4.8. Phosphorylation of SIN1 at Ser-260 is dependent on the ATP-sensitive
mTORC2 activity
To further characterize the mTOR-dependent regulation of SIN1, we
attempted to identify SIN1 phosphorylation site. We applied the mTORC2
reconstitution system by co-expressing wild type mTOR or its kinase-dead form
with other three essential components (Xp-rictor, V5-SIN1 and HA-mLST8). By
pulling down V5-SIN1, the enriched samples from 10 immunoprecipitates were
applied for SDS-PAGE and Commassie Blue staining (Figure 4-8A). Mass





Figure 4-7.

The activity of the mTOR kinase complexes is sensitive to

ATP concentration.
(B) For mTORC2 kinase reaction, rictor immunoprecipitates prepared from
lysates of MDA-MB-435 cells were used for in vitro kinase assays with full-length
WT-Akt1 as the substrate and different amount of the ATP (0, 0.1, 0.2, 0.4, 0.6,
0.8, 1.2, 1.6, and 3.2 mM, respectively).





Figure 4-7.

The activity of the mTOR kinase complexes is sensitive to

ATP concentration.
(C) For mTORC1 kinase reaction, raptor immunoprecipitates prepared from
lysates of MDA-MB-435 cells were used for in vitro kinase assays with full-length
WT-S6K1 as the substrate and different amount of the ATP (0, 0.1, 0.2, 0.4, 0.6,
0.8, 1.2, 1.6, and 3.2 mM, respectively). Both kinase complexes require at least
1.2 mM ATP for full kinase activity.





Figure 4-8.

Identification of the mTOR-dependent SIN1 phosphorylation

site.
(A) Xpress-rictor, SIN1-V5, and HA-mLST8 constructs were cotransfected with
Myc-mTOR (wt) or Myc-mTOR (KD) in HEK-293T cells, respectively.
Immunoprecipitates prepared from lysates of HEK-293T cells with anti-V5
antibody were resolved in SDS-PAGE and visualized by Coomassie blue staining.
The potential SIN1 gel bands were excised and sent for Mass spectrometric
analysis.





spectrometric analysis was then carried out to determine the potential SIN1
phosphorylation site. Based on the mass spectrometry readings of the distinct
SIN1 peptides, Ser-260 has been verified with a high probability as the SIN1
phosphorylation site (Figure 4-8B).
To study the role of this SIN1 phosphorylation site, the anti-SIN1 (Ser-260)
antibody has been generated. The specificity of this antibody was validated by
examining its interaction to the wild type SIN1 or its phospho-mutant (S260A).
The phospho-SIN1 (Ser-260) antibody did not recognize its mutated epitope and
exhibited high specificity (Figure 4-8C). We applied this specific phospho-SIN1
(Ser-260) antibody to analyze the SIN1 phosphorylation in response to glucose
deprivation. We observed that phosphorylation of SIN1 at Ser-260 decreased
after glucose starvation for 16 hours, but not at amino acid deprivation condition
(Figure 4-8D). In this setting, we also detected the disassembly of mTORC2 after
16 hours glucose depletion (Figure 4-6B). Thus, phosphorylation of SIN1 Ser-260
may play an important role for maintaining mTORC2 integrity.
We analyzed the SIN1 protein sequence and found that Ser-260 is located
within the highly conserved region, which was designated as the Box1 (residues
225–267 of the human SIN1 sequence; Figure 4-8E). Box1 lays within the larger
region of unknown function referred as the Conserved Region In the Middle
(CRIM), a highly conserved domain (residues 140–267). It suggests that the Ser260 phosphorylation site within CRIM is critical for SIN1 stability. On the other
hand, mTOR is known to prefer to phosphorylate serine





Figure 4-8.

Identification of the mTOR-dependent SIN1 phosphorylation

site
(B) Phosphorylation of Ser-260 in SIN1 identified by MS/MS. SDS-PAGE
purification followed by enzymatic digestion and LC/MS/MS was used to isolate
peptide containing phosphorylated serine residue in position 4 (S*). Expected
masses for the y and b ions are listed above and below the peptide sequence.
Ions that were positively identified are highlighted in blue and red. Y ions at 940.5
and 773.5 define the phospho-serine residue at position 4. The abundant ion at
597.5 is the neutral loss of 98 Da from the doubly charged parent ion.





Figure 4-8.
(C) Cross validation of the p-SIN1 (Ser-260) antibody. The V5 tagged wild type or
SIN1 Ser-260A phospho-mutant was expressed in HEK-293T cells and
immunopurified using V5 antibody. The immunopurified wild type and phosphomutant SIN1 proteins were analyzed by western blotting with the phospho-SIN1
(S260) and V5 antibodies.





Figure 4-8.
(D) Glucose starvation results in dephosphorylation of SIN1 Ser-260 in MDA-MB435 cells. MDA-MB-435 cells were incubated in plus or minus glucose medium
for 10 and 16 hours. The cells were also incubated in 10 % serum medium or
amino acid-free medium for 16 hours as controls. The SIN1 protein was
immunopurified

with

anti-SIN1

antibody.

The

dephosphorylation

of

the

endogenous SIN1 in MDA-MB-435 cells occurs after 16 hours of glucose
starvation.





Figure 4-8.
(E) SIN1 protein domains: CRIM: conserved region in the middle; RBD: Raf-like
Ras-binding domain; PH: pleckstrin homology. Box1 (amino acids 225-267) is the
highly conserved region located within the CRIM domain. mTOR kinasedependent SIN1 site (Ser-260) resides in the Box1, implying the significant role
of this phosphorylation site. The Serine residue of SIN1 and the known mTORC2
substrates: Akt, SGK1 and PKC are surrounded by hydrophobic amino acids.

* indicates the hydrophobic amino acids.





residues within the hydrophobic motif. For instance, the well-studied mTORC2
substrates: Akt Ser-473, SGK1 Ser-422 and PKC Ser-657 are located in the
regions containing hydrophobic amino acids. The SIN1 Ser-260 site also
represents the hydrophobic motif suggesting that mTOR might be a potential
kinase of this site (Figure 4-8E).
To prove that mTOR is the SIN1 Ser-260 kinase, we studied the SIN1
phosphorylation by the in vitro mTORC2 reconstitution as described in Figure 43B. After co-incubation of the FLAG-mLST8/myc-mTOR and myc-rictor/V5-SIN1,
these two heterodimers have assembled into functional mTORC2. Also, the
increased SIN1 Ser-260 phosphorylation after mTORC2 assembly indicated that
SIN1 is the substrate of mTOR kinase (Figure 4-8F).

4.9. The SIN1 Ser-260 site is ATP dependent and regulates SIN1
degradation and mTORC2 assembly
We have shown that the ATP depletion by the prolonged glucose
starvation led to SIN1 dephosphorylation and its degradation. To test other
physiological conditions that cause ATP depletion, we treated the MDA-MB-435
cells with 5 mM 2-DG and 10 μM rotenone in the time-dependent manner and
found that SIN1 degradation occurred after 2 hours of drugs treatment (Figure 49A). We applied the lysates from cells with 1 hour drugs treatment for SIN1
immunoprecipitation and observed the decreased SIN1 Ser-260 phosphorylation
and the disassembly of the mTORC2 (Figure 4-9B). In this condition, the
treatment of 2-DG and rotenone led to acute ATP depletion (White et al., 2002)





Figure 4-8.

mTOR is the kinase for SIN1 Ser-260 phosphorylation.

(F) In vitro mTORC2 assembly was performed by incubation of two heterodimers,
rictor/Sin1 and mTOR/mLST8 as mentioned in Figure 4-3B. The result showed
the in vitro assembly of two heterodimers (rictor/Sin1 and mTOR/mLST8) and
direct phosphorylation of SIN1 (slower migratory form and detection of the
phospho-SIN1 S260 signal) by mTOR. The in vitro assembled mTORC2 is a
functional complex that contains the kinase activity toward Akt and SIN1.





Figure 4-9.

ATP depletion causes dephosphorylation of SIN1 Ser-260,

mTORC2 complex dissociation, and SIN1 degradation.
(A) Acute ATP depletion leads to decreased SIN1 protein abundance. MDA-MB435 cells were incubated with 5 mM 2-DG and 10 μM rotenone in glucose-free
medium for 1, 1.5 and 2 hours.
(B) Acute ATP depletion leads to dephosphorylation of SIN1 Ser-260 and
mTORC2 complex dissociation. MDA-MB-435 cells were incubated with 5 mM 2DG and 10 μM rotenone in glucose-free medium for 1 hour. The SIN1
immunoprecipitates were prepared from cell lysates to examine the complex
formation of the mTORC2.





and similar effects on mTORC2 that is caused by prolonged glucose starvation.
These results indicate that the acute ATP-depletion is sufficient to cause
dephosphorylation of SIN1 on Ser-260, SIN1 degradation, and deficiency of the
mTORC2 integrity.

4.10. The mTOR-dependent phosphorylation of SIN1 at Ser-260 regulates
SIN1 protein stability and maintains mTORC2 integrity
We hypothesized if Ser-260 in SIN1 is the main regulatory residue in the
mTORC2 complex, mutation of this residue will alter SIN1 protein stability and
mTORC2 integrity. We generated the SIN1 phospho-mutants by substituting the
Ser-260 to alanine (S260A that prevents phosphorylation) or aspartic acid
(S260D that mimics phosphorylation), and applied the mutant constructs to the
mTORC2 reconstitution system. In the cotransfection with mTOR-WT, the SIN1
(S260A) mutant showed less protein abundance compared to wild-type SIN1 and
S260D mutant (Figure 4-10A). In the co-expression with mTOR-KD, wild-type
SIN1 that failed to be phosphorylated by functional mTOR kinase displayed low
protein abundance, similar to the S260A mutant. However, S260D mutant of
SIN1 that mimics the mTOR-dependent phosphorylation remained insensitive to
the mTOR kinase activity (Figure 4-10A).
To further analyze mTORC2 assembly, we optimized SIN1 expression by
co-expressing distinct amount of the cDNAs encoding wild-type SIN1 and its
phospho-mutants (Figure 4-10B). To optimize expression of the unstable S260A
mutant, we co-transfected with mTOR-WT only 30 % amount of the cDNAs





Figure 4-10. SIN1 Ser-260 phosphorylation is required for its protein
stability.
(A) The V5 tagged wild type or phospho-specific SIN1 recombinant proteins
(S260D and S260A) were co-expressed with myc-mTOR (wt) or myc-mTOR (KD),
respectively, and another two mTORC2 components (Xp-rictor and HA-mLST8)
in HEK-293T cells. The total cell lysates and immunoprecipitates purified using
Myc antibody was analyzed by western blotting with the indicated tag antibodies.





Figure 4-10. SIN1 Ser-260 phosphorylation is required for mTORC2
complex integrity
(B) The V5 tagged wild type or phospho-specific SIN1 recombinant proteins
(S260D and S260A) were co-expressed with myc-mTOR (wt) or myc-mTOR (KD),
respectively, and another two mTORC2 components (Xp-rictor and HA-mLST8)
in HEK-293T cells. To optimize the SIN1 expression, the myc-mTOR-WT was cotransfected with 30 % of V5-SIN1-WT, 30 % of V5-SIN1-S260D or 100 % of V5SIN1-S260A. The myc-mTOR-KD was co-transfected with 100 % of V5-SIN1-WT,
30

%

of

V5-SIN1-S260D

or

100

%

of

V5-SIN1-S260A.
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immunoprecipitates were prepared from cell lysates to examine the complex
integrity of the mTORC2.





encoding wild-type SIN1 and S260D mutant. The immunoprecipitates with the
comparable abundance of mTORC2 reconstituted with wild-type SIN1 or its
phospho-mutants showed that SIN1 S260A mutant was not effective to form
mTORC2. This suggested that phosphorylation of SIN1 at Ser-260 is required to
retain complex integrity. In the cotransfection with mTOR-KD, only 30 % of the
cDNA encoding SIN1 S260D mutant was co-expressed. Under this setting, wildtype SIN1 that was unable to be phosphorylated by functional mTOR kinase was
incapable to assemble mTORC2, similar to the SIN1 S260A mutant (Figure 410B). In contrast, the SIN1 S260D mutant that mimics phosphorylation could
prevent complex dissociation and still remained in the complex with the kinase
dead mTOR. Collectively, the mTOR kinase-dependent phosphorylation of SIN1
at Ser-260 preserved the complex integrity of mTORC2 by stabilizing SIN1.

4.11. The mTOR-dependent phosphorylation of SIN1 at Ser-260 regulates
cell proliferation
To further examine the biological impact of the mTOR-mediated SIN1
phosphorylation at Ser-260, we generated the stable MEFs by restoring similar
amounts of SIN1-WT and its phospho-mutants into SIN1-deficient MEFs. We
detected a higher basal Akt Ser-473 phosphorylation in SIN1 S260D mutantrestored stable MEF compared to those restored with SIN1-WT or S260A mutant
(Figure 4-11A). We analyzed the complex integrity of mTORC2 in these stable
MEFs by SIN1 immunoprecipitation and found that SIN1 S260D mutant is more
effective in assembling mTORC2 compared to the wild-type SIN1





Figure 4-11.
(A) Stable expression of the SIN1 Ser-260D phospho-mutant showed high
basal phosphorylation of Akt at Ser-473 and more mTORC2 complex. SIN1null MEFs stably expressing WT-SIN1 or the phospho-mutants and grown in 10
% serum-containing medium. SIN1 immunoprecipitates from stable MEFs were
used to examine the complex integrity of the mTORC2.





or its S260A mutant (Figure 4-11A). This supports our previous results that
phosphorylation of SIN1 at Ser-260 preserved mTORC2 integrity and this
complex carried a higher activity.
Since Akt controls cell proliferation, we hypothesized that SIN1 S260D
mutation might more robustly promote cell proliferation compared to SIN1-WT or
S260A mutant. To test this hypothesis, we examined the proliferation rate of the
SIN1-restored stable MEFs after incubated in 10 % FBS-containing medium for
48 and 72 hours (Figure 4-11B). First, the proliferation rate of the SIN1-deficient
MEFs

increased

by

restoration

of

SIN1-WT

(~1.6

times

relative

to

unreconstituted SIN1-deficient MEFs). Restoration of the SIN1 S260D mutant
had more potent effects on cell proliferation compared to that of SIN1-WT (~1.9
times compared to unreconstituted SIN1-deficient MEFs and 40 % higher than
SIN1-WT-restored MEFs). The MEFs expressing the SIN1 S260A mutant did not
proliferate to the same degree as those expressing either WT or S260D mutant
(~1.3 times relative to unreconstituted SIN1-deficient MEFs and 60 % less than
MEFs restored with SIN1-WT). These results are coherent with the effects of
these mutants on mTORC2 signaling (Figure 4-11A). Those MEFs restored with
SIN1 S260D mutant proliferated at the three times higher rate than those
reconstituted with S260A mutant. It indicates that regulation of this site is critical
for the mTORC2-dependent cell proliferation.
Because mTORC2 kinase activity is sensitive to cellular glucose levels,
we studied effects of high (5.5 mM) and low (0.55 mM) glucose concentration on
these SIN1 stable MEFs by analyzing cell proliferation. After incubation at 5.5





Figure 4-11.
(B) Phosphorylation of SIN1 at Ser-260 up-regulates cell proliferation. WTSIN1 or the phospho-mutants were reintroduced into SIN1-null MEFs with the
retroviral expression system. Cell proliferation measurements were performed by
counting cells 48 and 72 hours after incubation in 10 %-FBS containing medium.
The ratio of proliferation rate was graphed with GraphPad Prism 5 software.





mM glucose for 48 hours, we observed a higher basal Akt Ser-473
phosphorylation in the wild-type SIN1 and S260D mutant-expressing stable
MEFs compared to those expressing the S260A mutant (Figure 4-11C). The Akt
signaling activity is consistent with the higher proliferation rate of MEFs
reconstituted with the wild-type SIN1 or S260D mutant (Figure 4-11D).
When the stable MEFs were incubated at 0.55 mM glucose for 48 hours,
we detected a stronger Akt Ser-473 phosphorylation only in MEFs expressing the
SIN1 S260D mutant that exhibited the higher SIN1 protein abundance (Figure 411C). The SIN1 S260D expressing MEFs displayed a higher proliferation rate
compared to those reconstituted with the wild-type SIN1 and S260A mutant as
shown in. Figure 4-11D. These results indicate that phosphorylation of SIN1 at
Ser-260 maintains mTORC2 integrity and regulates cell proliferation in high or
low glucose cell culture conditions.

4.12. mTOR-dependent phosphorylation of SIN1 at Ser-260 regulates tumor
growth
To address a role of SIN1 phosphorylation in vivo, we studied the effects
of SIN1 Ser-260 phosphorylation on tumor growth. To develop tumor growth, we
transformed MEFs restored by WT or mutant SIN1 by overexpressing equal
amount of H-Ras (Figure 4-12A). Mice injected with the wild-type SIN1 and
S260D mutant-reconstituted MEFs had bigger tumors than those injected with
MEFs restored with SIN1 S260A mutant (Figure 4-12A and B). These results
show that mTOR kinase-dependent SIN1





Figure 4-11.
(C) SIN1-null MEFs stably expressing SIN1 Ser-260D phospho-mutant showed
high basal phosphorylation of Akt at Ser-473 in 5.5 mM or 0.55 mM glucose
containing-mediums with the addition of 100 ng/ml IGF-1 for 48 hours.
Immunoblotting was used to detect the indicated proteins in cell lysates.





Figure 4-11.
(D) SIN1-null MEFs stably expressing SIN1 Ser-260D phospho-mutant
exhibited higher proliferation rate in physiological and low glucose
conditions. Cell proliferation measurements were performed by counting cells
48 hours after incubation in 5.5 mM or 0.55 mM glucose-containing mediums
with the addition of 100 ng/ml IGF-1 for 48 hours. The ratio of proliferation rate
was graphed with GraphPad Prism 5 software.





Figure 4-12. Blocking Ser-260 phosphorylation of SIN1 inhibits tumor
growth.
(A) MEFs described in Figure 4-11A were transformed by overexpression of the
oncogenic form of H-Ras and injected into 6-week-old immunodeficient nude
mice (n = 5 for each group; 3106 cells per mouse). Tumor size was measured
after 3, 4 and 5 weeks; the tumor sizes were calculated and the volumes were
presented by line graph.





Figure 4-12. Blocking Ser-260 phosphorylation of SIN1 inhibits tumor
growth.
(B) Mice injected with MEFs expressing each form of SIN1 were sacrificed and
representative images of the excised tumors are shown.





phosphorylation at Ser-260 is pivotal in the regulation of cell proliferation and
tumor growth.

4.13. Discussion
Our study demonstrates that the co-transfection of the essential
components of mTORC2 (mTOR, mLST8, SIN1 and rictor) is able to assemble
the functional complex with the growth factor-dependent kinase activity. We
employed the reconstituted mTORC2 to study the role of the mTOR kinase
domain within mTORC2 to execute Akt phosphorylation at Ser-473. The original
intention was to eliminate the possibility that unknown kinase co-purified with
mTORC2 may serve as the Akt Ser-473 kinase. As we expected, the substitution
of the mTOR-WT with its kinase-dead form prevented mTORC2 kinase activity
toward Akt. Our data distinctly demonstrates that mTOR kinase within the
complex of mTORC2 is necessary for Akt phosphorylation at the regulatory Ser473 site. This excludes a possibility of any other kinase that may associate with
mTORC2 and phosphorylate Akt.
The analysis of the mTORC2 reconstitution system also results in the
interesting finding implying the essential role of mTOR kinase in controlling
mTORC2 integrity. Moreover, the mTOR kinase activity is required to preserve
the protein stability of SIN1 by protecting it from lysosomal degradation. The
reconstitution of mTORC2 with the mTOR-KD isoform leads to a rapid SIN1
protein turnover dependent on SIN1 phosphorylation as observed by the
phosphatase-mediated SIN1 protein migration in the gel. The mTOR-mediated





SIN1 phosphorylation does not occur when only SIN1 and rictor are cotransfected in cells and form a heterodimer. Importantly, the mTOR-dependent
SIN1 phosphorylation happens only after reconstitution of the functional
mTORC2. It clarifies a specific role of the mTOR kinase on SIN1 phosphorylation.
Most likely, SIN1 within mTORC2 complex is constitutively phosphorylated by
mTOR kinase and this post-translational modification prevents the accelerated
SIN1 protein degradation. Moreover, the mTOR-mediated SIN1 phosphorylation
is independent on growth factor signaling since we do not observe mTORC2
dissociation or SIN1 degradation in cells under serum starvation. Thus, a basal
mTOR kinase activity in this complex is sufficient to sustain SIN1 phosphorylation.
In addition to growth factors, mTOR activation is nutrient dependent (such
as glucose and amino acids) (Guertin and Sabatini, 2007). To identify the
physiological conditions that affect mTOR-dependent SIN1 phosphorylation, we
provided nutrients-depletion conditions by incubation of cells in glucose-free or
amino acids-free cell culture conditions. We found that only glucose starvation
caused SIN1 degradation and mTORC2 disassembly. Glucose is the essential
energy source for cells to produce ATP. Therefore, the glucose starvationmediated ATP depletion may suppress mTOR function. Indeed, we confirmed
that mTOR kinase that either exists in mTORC1 or mTORC2 requires at least 1.2
mM ATP for its full activity indicating its low ATP binding capacity. In contrast,
other common kinases need only 0.1 mM ATP for their activity (Dennis et al.,
2001). It emphasizes that mTOR kinase activity is highly sensitive to the low
cellular ATP concentration associated with metabolic stress. These results





explained why glucose starvation-dependent ATP deprivation led to mTOR
inactivation and compromised SIN1 phosphorylation causing a potent negative
impact on the mTORC2 integrity.
Our biochemical study of SIN1 phosphorylation identified the potential
SIN1 phosphorylation site by mTOR as Ser-260. This site carries two important
features. First, SIN1 possesses a highly conserved region at Box1 of the
Conserved Region in the Middle (CRIM) domain that is homologous from human
to drosophila. The Ser-260 site locates within the evolutionally conserved Box1
and may play a significant role for SIN1 function. Second, the Ser-260 site
locates within the hydrophobic motif of SIN1. Previous studies showed that
mTOR kinase phosphorylates the serine residue within the hydrophobic motifs,
identified in its known substrates: Ser-473 of Akt, Ser-422 of SGK1 and Ser-657
of PKC (Alessi et al., 2009). By performing the in vitro assembly of mTORC2,
we found that SIN1 as the component of mTORC2 is the substrate of mTOR. On
the other hand, we developed a specific phospho-antibody against Ser-260
phosphorylation of SIN1 and showed that phosphorylation of SIN1 at Ser-260
reduced upon mTOR inactivation that was caused by ATP depletion. Thus we
identified that mTOR phosphorylates SIN1 on the Ser-260 site.
Our work showed the significance of SIN1 phosphorylation at Ser-260 by
expressing its phospho-mutants (S260D and S260A) in SIN1 null cells. The SIN1
S260D mutant that mimics phosphorylation could preserve the complex integrity
by preventing SIN1 protein degradation. Importantly, a substitution by the wild
type SIN1 to its S260D phospho-mutant in MEFs displayed a higher mTORC2





activity, cell proliferation and tumor growth rates. Our results point out an autoregulatory mechanism of mTORC2 by constitutive phosphorylation of SIN1 at
Ser-260 by mTOR (Figure 4-13). The physiological ATP concentration (1~5 mM)
is sufficient to maintain basal mTOR kinase activity. Once cells encounter a
metabolic stress causing a dramatic decrease of ATP level, the ATP-sensitive
mTOR kinase fails to sustain SIN1 phosphorylation causing SIN1 degradation
and

mTORC2

dissociation.

Therefore,

the

auto-regulatory

mechanism

temporarily shut down the ATP-consuming cell proliferation machinery and
anabolic processes by disrupting mTORC2 under metabolic stress.
Phosphorylation of SIN1 at Ser-260 prevents its protein degradation and
preserves the complex integrity of mTORC2 that further triggers the Aktdependent anabolic processes and inducing cell proliferation. Thus, our findings
provide a novel insight how the homeostatic ATP sensor regulates the mTORC2
integrity by SIN1 phosphorylation on Ser-260.





Figure 4-13. ATP-sensitive mTOR kinase-mediated phosphorylation of
SIN1 at Ser-260 is required to preserve complex integrity of mTORC2 by
preventing SIN1 degradation
The mTOR kinase has lower ATP binding affinity and requires sufficient cellular
ATP concentration. The physiological ATP concentration is 1~5 mM that is
enough to maintain the full mTOR kinase activity. In addition, the mTOR kinase
activity is required for SIN1 phosphorylation at Ser-260, which is critical for
maintaining complex integrity and SIN1 stability. When cells encounter metabolic
stresses that decline cellular ATP level, deficient mTOR kinase fails to maintain
the phosphorylation of SIN1 at Ser-260, which results in mTORC2 complex
dissociation and SIN1 degradation.





Chapter 5
Future Directions





Our findings identify two distinct regulatory mechanisms of the anabolic
signaling complex mTORC2 under ER stress and metabolic stress. In Chapter 3,
our study provides a novel insight in the regulation of mTORC2 under ER stress
that defines the overlooked balance between two kinases, Akt and GSK-3.
Initially, GSK-3 has been identified as a substrate of Akt. In our study, we
showed that ER stress-inducible GSK-3 becomes the stress inducible upstream
regulator of the mTORC2-Akt signaling. The phosphorylation of rictor on Ser1235 by GSK-3 impairs the substrate binding of mTORC2 and inhibits its kinase
activity.
Under ER stress, the GSK-3 kinase is activated as detected by the
phosphorylation of its substrate glycogen synthase (Ser-641) and autophosphorylation site (Tyr-216). However, how ER stress regulates the activity of
GSK-3 remains unknown. To identify the regulatory components of GSK-3, we
will apply several biochemical approaches:
(1) Immunoprecipitation: we will immunopurify GSK-3 from cells either under ER
stress or with treatment of GSK-3 inhibitor, and then subject the samples to
silver staining analysis. Following identification of the potential regulators by
Mass Spectrometry analysis, we will study the impacts of the novel GSK-3
regulators on the activity of GSK-3 by expression of the recombinant proteins
and specific shRNAs.
(2) Size exclusion chromatography: the biochemical purification of the GSK-3
regulators is the most challenging and difficult task. We have preliminary data
based on the enrichment of the GSK-3 through size exclusion chromatography.





GSK-3 is located in the fractions of the molecular weight more than 60 kDa
while the molecular weight of GSK-3 monomer is 46 kDa. This finding indicates
that regulator might associate with GSK-3 in a complex. In this co-purification
study the different types of detergents and chemical cross-linkers will be applied
to stabilize the GSK-3 complex.
As an alternative approach to enrich the regulators we will perform the
differential centrifugation prior to size exclusion chromatography. Differential
centrifugation is a useful technique to separate the organelles from a
homogenous solution of particles based on their densities. In this case, we can
pre-isolate the cell fractions containing the GSK-3 effectors before the next-step
purification. Moreover, we will conduct the ionic exchange chromatography to
further purify and enrich the effectors. When we obtain the relatively pure
fraction, we will perform mass spectrometric analysis to identify the specific GSK3 regulators.
The biological relevance of mTORC2 regulation by ER stress is an
important part of our future studies. ER stress is highly associated with metabolic
diseases including type II diabetes. The initial stage of the type II diabetes is
characterized by insulin resistance-- the peripheral tissues (muscle, fat and liver)
fail to respond to insulin, leading to deficient glucose uptake. Previous mouse
genetic models also linked GSK-3 with insulin resistance. GSK-3 is linked to
insulin signaling by phosphorylating glycogen synthase known to lead to
inhibition of glycogen synthesis and decrease of the cellular sensitivity to insulin.
In our study, the negative regulation of Akt by GSK-3 may represent another





mechanism that contributes to insulin resistance.
To study the effects of rictor Ser-1235 phosphorylation on Akt-dependent
glucose metabolism, we are in a process of generating rictor “phospho-mutantsknock-in” mice and analyze their phenotypes. It becomes clear that obesity
causes ER stress and contributes to the development of type II diabetes. We will
feed the rictor “phospho-mutants-knock-in” mice with high-fat diet (HFD) to
induce obesity and ER stress. Then, we will conduct glucose tolerance tests
(GTT) and insulin tolerance tests (ITT) in these mice to examine their systemic
insulin sensitivity and glucose homeostasis.
To follow up the studies of the mouse phenotype, we plan to apply MEFs
from the rictor “phospho-mutants-knock-in” mouse embryos, and study the
impact of GSK-3-mediated rictor phosphorylation on glucose uptake. To dissect
the effects of GSK-3 on glucose uptake, we will first treat the MEFs with ER
stress inducers (thapsigargin or tunicamycin) to activate GSK-3. Subsequently,
we will apply 2-NBDG (a new fluorescent derivative of glucose) and measure the
rates of glucose uptake. Alternatively, we will test other insulin-sensitive tissues,
such as skeletal muscle, adipose or liver tissues, to observe more significant
glucose uptake.

Our studies also define the ATP-dependent auto-regulation of mTORC2.
In Chapter 4, our results indicate that mTOR is a highly sensitive kinase to the
cellular ATP level under metabolic stress induced by glucose deprivation or acute
ATP depletion. We found that mTOR is the Ser-260 kinase of SIN1. Without





phosphorylation at Ser-260 by functional mTOR kinase, SIN1 remains unstable
and undergoes lysosomal degradation. Our data indicate that SIN1 Ser-260
phosphorylation is required to maintain SIN1 stability and complex integrity. Does
this phosphorylation event directly control mTORC2 assembly or indirectly
preserve complex integrity by simply protecting SIN1 from lysosomal
degradation?
To test the first possibility, we will apply SIN1-WT and its phosphomutants to the in vitro mTORC2 reconstitution system (Chen and Sarbassov dos,
2011). If the SIN1 mutants do not affect the complex assembly, then we will
examine the second possibility. To check if SIN1 phosphorylation indirectly
maintains mTORC2 integrity, we will treat the SIN1-WT, S260D, and S260Arestored MEFs with the lysosomal inhibitor (chloroquine), and analyze the
complex by SIN1 immunoprecipitation. If the inhibition of SIN1 degradation can
enrich the complex level of mTORC2 containing SIN1-S260A mutant, then the
second possibility is correct.
Moreover, how SIN1 phosphorylation prevents its lysosomal degradation
is an intriguing question. Autophagy is a cellular catabolic process that integrates
with lysosome for protein degradation. To study if autophagy is involved, we can
knock down the critical components of the autophagic pathway (ATG5 and
ATG7) using the shRNA lentiviral system. To further analyze SIN1 transportation
to lysosomes for degradation, we will purify the lysosomal fractions from
metabolic stressed cells treated with or without chloroquine, and determine SIN1
protein amount. This biochemical study will validate if SIN1 protein is directly





targeted to lysosome for degradation.
The SIN1 Ser-260 phospho-mutants will be highly valuable because the
SIN1 S260D mutant is much more stable form and targeting of SIN1 for
degradation is prevented by its Ser-260 phosphorylation. We propose that
assembly of the SIN1 lysosomal targeting complex will be actively formed with
the wild type or its S260A mutant but not with its phospho-mimetic S260D
mutant. Based on this assumption, we will focus on identification of the proteins
co-purified with the wild type SIN1 or S260A mutant. We will extend this study by
characterizing the SIN1 complex in the lysosomal fractions that might lead to
understanding of the selective lysosomal degradation pathway. The identified
components of the SIN1 degradation complex will be validated by expression of
the recombinant proteins and also specific shRNAs.
In our study, the ATP-sensing mechanism of mTORC2 explains how this
anabolic signaling complex disintegrates under metabolic stress. Another stress
responsive kinase, AMPK (AMP-activated protein kinase), is activated by low
cellular ATP level. It is possible that AMPK may involve in the regulation of the
mTORC2 under metabolic stress. To test this possibility, we will apply the AMPK
inhibitor (Compound C) in cells under glucose starvation or acute ATP depletion
conditions and study the mTORC2 activity, integrity, and SIN1 stability.
Alternatively, we may employ the AMPK-null MEFs to see if AMPK contributes to
mTORC2 regulation.

Overall, we identify two different regulatory mechanisms of mTORC2 by





the essential components rictor and SIN1. These two projects provide novel
insights into the regulation of mTORC2 under cellular stress conditions. We will
need the future studies to extend our knowledge in the field of the mTORC2-Akt
signaling pathway.
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